

Review

Biological Activities of Lactose-Based Prebiotics and Symbiosis with Probiotics on Controlling Osteoporosis, Blood-Lipid and Glucose Levels

Arijit Nath ^{1,2,*}, Máté András Molnár ¹, Attila Csighy ¹, Kornélia Kőszegi ¹, Ildikó Galambos ² , Klára Pásztorné Huszár ³, András Koris ¹ and Gyula Vatai ^{1,*}

¹ Department of Food Engineering, Faculty of Food Science, Szent István University, Ménesi st 44, HU-1118 Budapest, Hungary; Molnar.Mate@etk.szie.hu (M.A.M.); Attila.Csighy@phd.uni-szie.hu (A.C.); koszegi.laszlone@etk.szie.hu (K.K.); Koris.Andras@etk.szie.hu (A.K.)

² Soós Ernő Water Technology Research Centre, Faculty of Engineering, University of Pannonia, Üllő út., H-3 Nagykanizsa, Hungary; galambos.i@sooswrc.hu

³ Department of Refrigeration and Livestock Product Technology, Faculty of Food Science, Szent István University, Ménesi st 43–45, HU-1118 Budapest, Hungary; Pasztorne.Huszar.Klara@etk.szie.hu

* Correspondence: arijit0410@gmail.com (A.N.); Vatai.Gyula@etk.szie.hu (G.V.); Tel.: +36-1-305-7110 (A.N.); +36-1-305-7115 (G.V.); Fax: +36-1-305-6323 (A.N.)

Received: 17 November 2018; Accepted: 28 November 2018; Published: 3 December 2018



Abstract: Lactose-based prebiotics are synthesized by enzymatic- or microbial- biotransformation of lactose and have unique functional values. In this comprehensive review article, the biochemical mechanisms of controlling osteoporosis, blood-lipid, and glucose levels by lactose-based prebiotics and symbiosis with probiotics are reported along with the results of clinical investigations. Interaction between lactose-based prebiotics and probiotics reduces osteoporosis by (a) transforming insoluble inorganic salts to soluble and increasing their absorption to gut wall; (b) maintaining and protecting mineral absorption surface in the intestine; (c) increasing the expression of calcium-binding proteins in the gut wall; (d) remodeling osteoclasts and osteoblasts formation; (e) releasing bone modulating factors; and (f) degrading mineral complexing phytic acid. Lactose-based prebiotics with probiotics control lipid level in the bloodstream and tissue by (a) suppressing the expressions of lipogenic- genes and enzymes; (b) oxidizing fatty acids in muscle, liver, and adipose tissue; (c) binding cholesterol with cell membrane of probiotics and subsequent assimilation by probiotics; (d) enzymatic-transformations of bile acids; and (e) converting cholesterol to coprostanol and its defecation. Symbiosis of lactose-based prebiotics with probiotics affect plasma glucose level by (a) increasing the synthesis of gut hormones plasma peptide-YY, glucagon-like peptide-1 and glucagon-like peptide-2 from entero-endocrine L-cells; (b) altering glucose assimilation and metabolism; (c) suppressing systematic inflammation; (d) reducing oxidative stress; and (e) producing amino acids. Clinical investigations show that lactose-based prebiotic galacto-oligosaccharide improves mineral absorption and reduces hyperlipidemia. Another lactose-based prebiotic, lactulose, improves mineral absorption, and reduces hyperlipidemia and hyperglycemia. It is expected that this review article will be of benefit to food technologists and medical practitioners.

Keywords: lactose-based prebiotics; probiotics; osteoporosis; blood lipid level; blood glucose level

1. Introduction

Scientific advancements in biotechnology provide new methods for the synthesis of prebiotics from dairy sources and their applications in food-, biopharmaceutical-, and medical-sectors [1,2]. Prebiotics can be defined as “indigestible fermented food substrates that selectively stimulate the

growth, composition and activity of microflora in gastrointestinal tract and thus improve hosts' health and well-being" [3]. Several biological outcomes due to the interaction of prebiotics with probiotics are presented in Figure 1.




Figure 1. Biological outcomes due to symbiosis of prebiotics and probiotics (self-developed, figure compiled by authors based on Tadesse, 2012 [4]; Al-Sheraji et al., 2013 [5]; Markowiak and Śliżewska, 2017 [6]).

Different types of lactose-derivatives, such as galacto-oligosaccharide, lactosucrose, tagatose, lactulose, lactitol, lactobionic acid, and gluconic acid are produced through different enzymatic reactions (hydrolysis, transgalactosylation, isomerization, fructosyl-transfer, reduction, and oxidation), and microbial fermentation processes. They fulfill all criteria to become a member in the prebiotics family [7,8]. Lactose-based prebiotics are confirmed as 'safe' by the Food and Drug Administration Federal agency [9] and have unique biochemical importance [7,8,10]. Because of these reasons, medical practitioners frequently prescribe them as therapeutics. They are recommended for use in a pure form or together with dairy-based products or fruit juices to individuals of all ages [5,11]. When lactose-based prebiotics are consumed alone, their biological activities are expressed via interaction with gut microbiota, already present in intestine [12,13]. Lactose-based prebiotics are resistant from the acid hydrolysis in the stomach, bile salts, and hydrolyzing enzymes in the intestine [10]. However, in the stomach and the upper small intestine of a healthy adult human, microbial population around 10^4 colony forming units per milliliter, lactose-based prebiotics interact with facultative anaerobic or aerobic microbial communities, including *Lactobacillus* and *Streptococcus* in duodenum (microbial community approximately 10^3 colony forming units per milliliter); *Lactobacillus*, *Streptococcus*, *Staphylococcus*, and *Veillonella* in jejunum (microbial community approximately 10^4 colony forming units per milliliter) and *Enterobacteria*, *Enterococcus*, *Bacteroides*, *Clostridia*, *Lactobacillus*, and *Veillonella* in ileum (microbial population approximately 10^6 – 10^8 colony forming units per milliliter), parts of small intestine. Subsequently, they pass to caecum and enhance the activities and survival of the *Bacteroides*, *Clostridia* (*Clostridium coccoides* subgroup and *Clostridium leptum* subgroup). In the large intestine, lactose-based prebiotics interact strictly with anaerobes and obligate anaerobes (microbial population around 10^7 – 10^{12} colony forming units per milliliter), such as *Bacteroides*, *Peptostreptococcus*, *Eubacteria*, *Lactobacillus*, and *Clostridia*. Furthermore, in the recto-sigmoidal colon, they interact with *Streptococcus*, *Lactobacillus*, Bifidobacteria, *Bacteroides*, *Clostridia*, and Gammaproteobacteria [14,15].

Lactose-based prebiotics are converted to short chain fatty acids (acetic acid, propionic acid, and butyric acid), lactic acid, and gases (carbon dioxide, methane, and hydrogen) in the presence of gut microbiota. Research has proven that in the proximal colon and distal colon, the formations of short chain fatty acids are 70 to 140 mmol L⁻¹ and 20 to 70 mmol L⁻¹, respectively [16]. Furthermore, smaller quantities of formate, caproate, valerate, 2-methyl-butyrate, and isovalerate are produced by microbial fermentation of prebiotics. However, in general, acetate is predominant, followed by propionate and butyrate, formation of short-chain fatty acids depends on (a) molecular configuration of prebiotic (carbohydrate monomer, glycosidic linkage, and degree of polymerization); (b) interaction with gut bacteria; (c) saccharolytic capacities of prebiotic synthesized enzymes; and (d) fermentation mechanism [17]. Imbalance of microbiota in the gut creates dysbiosis and is a risk factor for several health hazards [18,19].

Consumption of lactose-based prebiotics, together with probiotics, offers some advantages due to their symbiotic activity [6,20]. However, the proliferation of intestinal microflora is a gradual process with age, and lactose-based prebiotics support the growth of probiotics due to the presence of *bgal*—*LacS* operon, which encodes transporter protein, enzymes for lactose hydrolysis, and metabolism [17,21]. A wide range of symbiotic outcomes, such as the restoration of gut microbiota, the maintenance of an equilibrium of gut microbiota, prevention against risks of several health hazards, development of immunity against pathogens, neutralization of toxins, and synthesis of added-value metabolites are well documented [12]. Table 1 shows the biochemical mechanisms for the synthesis of lactose-based prebiotics and biological outcomes due to symbiosis of lactose-based prebiotics and probiotics.

Table 1. Biochemical mechanisms for the synthesis of lactose-based prebiotics and biological outcomes due to symbiosis of lactose-based prebiotics and probiotics (self-developed, information were collected from Nath et al., 2016 [7]; Nath et al., 2017 [8]).

Lactose-Derived Prebiotics	Reaction Mechanisms	Biochemical Activities
Galacto-oligosaccharide	Transgalactosylation of lactose, galactose and glucose	Prevention of diarrhea, constipation, hyperlipidemia, and osteoporosis
Lactulose	Isomerization of lactose	Prevention of Crohn's disease, ulcerative colitis, hepatic encephalopathy, constipation, hyperlipidemia, hyperglycemia, and osteoporosis
Lactitol	Reduction of lactose	Prevention of hepatic encephalopathy and constipation
Lactosucrose	Fructosyl transfer	Prevention of Crohn's disease and ulcerative colitis
Lactobionic acid	Oxidation of lactose	Antioxidant and ultraviolet protector
Gluconic acid	Oxidation of glucose	Antioxidant and ultraviolet protector

Osteoporosis, hyperlipidemia, and hyperglycemia are common health hazards among all communities around the world. In adverse situations, they often cause death. Reduction of the risks of osteoporosis, hyperlipidemia, and hyperglycemia, by symbiosis of lactose-based prebiotics and probiotics, has been reported in several cases. In most cases, in vivo trials were conducted with animal and human models to verify the anti-osteoporosis, anti-hyperlipidemic, and anti-hyperglycemic effects of lactose-based prebiotics along with probiotics. These trials focused on outcomes, rather than understand the underlying biochemical mechanisms, which are therefore still unclear. Realizing the great potentialities of lactose-based prebiotics on human health, in this review article biochemical mechanisms and results of clinical investigations about controlling osteoporosis, blood- lipid, and glucose levels by lactose-based prebiotics and symbiosis with probiotics are reported in a comprehensive way.

2. Osteoporosis

Osteoporosis is a common complication, characterized by porous bone, improper bone mass, and reduced bone- density and strength [22]. There is a profound relationship between gastrointestinal disease and osteoporosis. Osteoporosis is associated with (a) maldigestion and malabsorption of

nutrients due to (a) celiac disease; (b) postgastrectomy; (c) short bowel syndrome; (d) inflammatory bowel diseases; (e) type 1 diabetes; (f) chronic liver disease; (g) gastroesophageal reflux disease; and (h) patients treated with total parenteral nutrition. Often patients suffer with osteoporosis after (a) liver and small bowel transplantation and (b) gastric bypass surgery [23,24]. Furthermore, overgrowth of gut microbiota, specifically Firmicutes, *Proteobacteria*, *Bacteroidetes* and *Actinobacteria* are also an important risk factor for osteoporosis [25,26].

2.1. Biochemical Mechanisms

Lactose-based prebiotics or their interaction with probiotics reduce osteoporosis and improve bone health [27–29] via different mechanisms. The mechanisms are (a) transformation of insoluble inorganic salts to soluble by short-chain fatty acids and increase their absorption to the gut wall; (b) maintenance and protection of mineral absorption surface in the gut by promoting the proliferation of enterocytes and colonocytes, integrating gut epithelium cells and improving intestinal barrier defending activity, down-regulating the formation and activity of nuclear factor kappa-light-chain-enhancer of activated B cells, reducing oxidative stress, immunomodulation, genetic modulation, and increasing antimutagenic activity; (c) increase the expression of calcium-binding proteins in the gut wall by increasing calbindin-D9k gene expression; (d) remodel the formation of osteoclasts and osteoblasts by increasing calcium uptake by suppressing the activities of parathyroid hormone and synthesis of insulin-like growth factor 1; (e) release of bone modulating factors; and (f) degradation of mineral complexing phytic acid [30–33]. The involvement of several gut microbiota, including probiotics, such as *Butyricococcus*, *Dialister*, *Oscillibacter*, *Lactobacillus*, *Lactococcus*, and *Bifidobacteria* reduce the risk of osteoporosis [34]. The detailed mechanisms of reduction of osteoporosis offered by lactose-based prebiotics and interaction with probiotics are presented in Figure 2 and subsequent sections.




Figure 2. Osteoporosis reduction mechanisms, offered by lactose-based prebiotics and interaction with probiotics. SCFAs: Short-chain fatty acids; TNF- α : Tumor necrosis factor- α ; IgA: Immunoglobulin A. (self-developed, figure compiled by authors based on Scholz-Ahrens et al., 2007 [31]; Whisner and Castillo, 2018 [32]; McCabe et al., 2015 [33]).

2.1.1. Conversion of Insoluble Inorganic Salts to Soluble and Their Absorption in the Gut

However, it has been reported that in the small intestine, dietary fibers may entrap or bind with inorganic minerals and inhibit their absorption. Fermented products of dietary fibers, i.e., short-chain fatty acids promote mineral absorption in the intestine [35]. Inorganic minerals are insoluble at a neutral pH [30]. Lactose-derivatives galacto-oligosaccharide [27,28] and lactulose [29] increase mineral absorption. In the intestine, lactose-based prebiotics are converted to short-chain fatty acids (butyric acid, acetic acid, and propionic acid) and lactic acid. As a result, the pH of the intestine reduces. In acidic pH, inorganic calcium [27–29], magnesium [29], iron [27], manganese [36], magnesium [37], boron [38], and copper and zinc [39] salts become soluble. This process promotes the colonic absorption of inorganic minerals to the gut. Inorganic minerals have play a significant role in the development of bone matrix constituents and they are essential cofactors for enzymes, involved in collagen synthesis [31,40].

2.1.2. Maintenance and Protection of Mineral Absorption Surface Area in the Gut

Lactose-based prebiotics and probiotics work symbiotically to improve bone health (reducing bone loss) by protecting the mineral absorption surface in the gut [22–24]. In the intestine, prebiotic-derived undissociated- and dissociated- short-chain fatty acids are absorbed to microvilli by passive diffusion and active transport mechanisms, respectively. Lactate and butyrate are absorbed through G-protein coupled receptors GPR41 and GPR43, and act as a growth factor of enterocytes and colonocytes [41]. Moreover, probiotic synthesized polyamine acts as a luminal mucosal growth factor in the host [42,43]. Due to the proliferation and enlargement of absorption surface area in the gut, mineral absorptions are increased [30]. Furthermore, lactose-based prebiotics and probiotics protect and maintain gut wall surface (mineral absorption surface area) [44,45]. The mechanisms are (a) integration of gut epithelium cells through the synthesis of antimicrobial agents (short-chain fatty acids [46,47], bacteriocins [48,49], antimicrobial peptides [50,51], mucin [52,53], collagen, fibronectin or fibrinogen [54–56], bacterial s-layer protein [57–59], and lectin-like protein [60,61]), and improvement of intestinal mucosal barrier defending activity through the development of a mucus layer [53,62,63], integration of tight junction, and alternation of cell surface proteins [64–66]; (b) down-regulation of the formation and activity of nuclear factor kappa-light-chain-enhancer of activated B cells [67,68]; (c) reduction of oxidative stress by glutathione [69], superoxide dismutase [70,71], catalase [72], glutathione peroxidase type 2 [73], and peroxiredoxins [74]; (d) immunomodulation [75–77]; (e) genetic modulation [78–80]; and (f) increase of antimutagenic activity [81–83].

2.1.3. Increase in the Activity of Calcium Binding Protein

Prebiotic-derived short-chain fatty acids, such as butyrate and propionate increase calbindin-D9k gene expression and are responsible for calcium binding protein synthesis via various mechanisms [84]. The probable mechanisms are (a) short-chain fatty acids directly enter cells and affect gene expression (inhibit the activity of histone deacetylase) [85,86] and (b) short-chain fatty acids bind with specific G-protein coupled receptors (GPR41 and GPR43), are present on cell membrane of the intestinal epithelial cells and affect calbindin-D9k transcription by intracellular signal transduction [87,88]. Upregulation of calcium binding protein increases bioavailability of key bone mineral, i.e., calcium within cells [89].

2.1.4. Bone Remodeling

Short-chain fatty acids take part in bone remodeling (suppression of bone-resorbing osteoclasts formation and upregulation of bone-forming osteoblasts formation). An increase of calcium uptake is associated with a high level of bone accrual [90] and suppression of the activities of the parathyroid hormone as well as bone resorption [91,92]. Short-chain fatty acids influence the synthesis of insulin-like growth factor 1, which takes part in bone remodeling [93,94]. Insulin-like growth

factor 1 can promote both bone resorption and formation via direct effects on osteoclasts [95] and osteoblasts [96,97], respectively. Moreover, local insulin-like growth factor 1 promotes bone growth and development in a significant way [98]. Lactose-based prebiotics support the growth of probiotics [99]. It has been reported that probiotic *Lactobacillus reuteri* ATCC PTA 6475 has the potential to suppress the activity of tumor necrosis factor α . It inhibits the Wnt10b RNA in osteoblasts when subjects have type 1 diabetes [100,101]. In another investigation, it has been suggested that *Lactobacillus reuteri* can suppress osteoclast activity in menopausal rodents [102]. Furthermore, *Lactobacillus reuteri* treatment has been shown to maintain bone health under low estrogen or estrogen-depleted conditions [102,103].

2.1.5. Release of Bone Modulating Factors

Lactose-based prebiotics stimulate the growth of *Lactobacillus* and Bifidobacteria. They maintain the population of gut microflora [104], and their synthesized β -glycosidase hydrolyzes the glycosidic bond of prebiotics. Subsequently, metabolites daidzein and equol are produced in a consequent way [105]. Equol is a nonsteroidal estrogen and plays a significant role in bone maintenance. Specifically, equol suppresses the expression of inflammatory-, osteoclastogenesis- and adipogenesis-related genes [106]. Under estrogen deficient conditions, galacto-oligosaccharide prevents bone loss in ovariectomized rats and mice [107]. Furthermore, the formation of equol from lactulose has been reported by several research groups [108,109].

2.1.6. Degradation of Mineral Complexing Phytic Acid

Humans and monogastric animals cannot produce endogenous phytase, which is responsible for the degradation of phytic acid, and is present as phytate form in cereal foods [110]. In enzymatic conversion, phytase hydrolyzes phosphomonoester bonds in phytate and transforms into an inorganic phosphate and a myo inositol phosphate derivative [111]. In the intestine, lactose-based prebiotics enhance the survival of probiotics and their activities [99]. They have the potential to synthesize phytase due to the presence of *appCBA* operon [112]. Consumption of prebiotics, along with probiotics, increases the bioavailability of trace elements, such as phosphate, copper, zinc, and iron. They play a significant role in bone development and the suppression of osteoporosis [113,114].

2.2. Clinical Investigations

Some clinical investigations have been performed with different types of lactose-based prebiotics, such as galacto-oligosaccharide and lactulose, to understand their effectiveness on mineral absorption. A randomized crossover study was performed with 12 healthy non-anemic males, aged 20 to 30 years, to investigate the effect of galacto-oligosaccharide on true intestinal absorption of iron and calcium. A double stable-isotope technique was adopted for experimental purposes. The subjects consumed a controlled basal diet supplemented with 15 g day⁻¹ inulin or fructo-oligosaccharide or galacto-oligosaccharide or without non-digestible oligo-saccharide (control diet). During the first 2 weeks of each type of diet, subjects were in a normal environment. On days 15 to 21 (last week) of each treatment, members consumed 0.05 g of non-digestible oligo-saccharide with orange juice at the start of breakfast, lunch, and dinner. Oral administration of ⁵⁷Fe and ⁴⁴Ca and intravenous ⁵⁸Fe and ⁴⁸Ca were used in the investigation. Iron absorption was measured on days 15 to 21 (the last 7 days of treatment) and calcium absorption was measured on day 21. It was found that there were no significant differences in calcium and iron absorptions. The authors concluded that 15 g day⁻¹ prebiotic treatment had no negative effect on iron and calcium absorptions in subjects [27]. van den Heuvel et al., performed a double-blind randomized crossover investigation with 12 post-menopausal women (mean age 62 years) to understand the function of galacto-oligosaccharide on true calcium absorption in mucosa. The experimental schedule consisted of two 9-days treatment periods, separated by a 19-day washout period. During first period, seven subjects received reference treatment (sucrose supplemented yogurt) and six subjects received 200 mL of yogurt twice a day (at breakfast and lunch) containing galacto-oligosaccharide 100 g L⁻¹. In the second period, the study protocol

was reversed. During treatment periods, subjects maintained their habitual food consumption and excluded the consumption of prebiotic- or probiotic- containing products. On the 8th day of each treatment period, ^{48}Ca and ^{44}Ca were administered intravenously and orally, respectively. It was found that the mean calcium absorption level was high in galacto-oligosaccharide yogurt-treated group compared to the control group. Moreover, total calcium excretion in urine after 36 h was low in galacto-oligosaccharide yogurt-treated group compared to the control group [28]. Another double-blind randomized, crossover investigation was performed by Seki et al., with 24 healthy adult male volunteers (mean age 33.5 ± 5.5 years). Test foods, containing 4 g (high-dose) or 2 g (low-dose) of lactulose together with 150 mg of magnesium and 300 mg of calcium were administered orally. In test food, 28 mg of ^{25}Mg and 20 mg of ^{44}Ca were present in 150 mg of magnesium and 300 mg of calcium, respectively. The subjects were randomly divided into three groups ($n = 8$ in each group), designated as group A, group B, and group C. At first ingestion period, members of group A, group B, and group C received a placebo formula, low-dose lactulose formula, and high-dose lactulose formula, respectively. After a wash out period of 2 weeks, in the second ingestion period, members of group A, group B, and group C received low-dose lactulose formula, high-dose lactulose formula, and a placebo formula, respectively. Subsequently, there was a 2-week washout period and in the third ingestion period, members of group A, group B, and group C received high-dose lactulose formula, a placebo formula, and low-dose lactulose formula, respectively. Concentrations of isotope ions were measured in urine samples. It was found that the least-square mean of urinary stable-isotopes ratios ($^{44}\text{Ca}/^{40}\text{Ca}$ and $^{25}\text{Mg}/^{24}\text{Mg}$) were increased in a dose-dependent manner. Significant differences in calcium and magnesium ratios between placebo-, low dose-, and high dose-lactulose-treated subjects were observed, and changes in Ca/creatinine and Mg/creatinine had similar trends [29].

3. Controlling Blood Lipids

Cardiovascular disease is the result of hyperlipidemia or dyslipidemia in elderly individuals. High levels of low-density lipoprotein cholesterol, triglyceride-rich lipoproteins, and low levels of high-density lipoprotein cholesterol in circulatory system are widely recognized risk factors for cardiovascular diseases (atherosclerosis, coronary heart diseases), which may be the result of consumption of an unhealthy diet containing high amounts of fat, salts, and simple carbohydrates [115]. It has been reported that the risk of a heart attack is three times higher in hypercholesterolemic patients, compared to normal individuals [116]. Different types of hyperlipidemia are primary hyperlipoproteinemia, polygenic hypercholesterolemia, familial combined hyperlipidemia, familial dysbetalipoproteinemia, familial hypertriglyceridemia, and endogenous hypertriglyceridemia [117]. Risk factors for hyperlipidemia in individuals includes (a) high age; (b) sex (generally men suffer with coronary heart disease and women may suffer after menopause); (c) family history; (d) type 2 diabetes or insulin resistance; (e) above average weight or obesity; (f) high cholesterol and triglycerides accumulation in blood transportation system, and consequently high blood pressure; (g) sleep apnea; (h) presence of high sensitivity C-reactive protein; (i) high level of homocysteine; (j) preeclampsia during pregnancy; (k) autoimmune diseases (rheumatoid arthritis and lupus); (l) high stress; (m) smoking; (n) consumption of alcohol and unhealthy diet; and (o) low physical activity and sedentary lifestyle [118,119]. Overgrowth of gut microbiota, such as *Eggerthella*, *Akkermansia*, *Christensenella*, *Tenericutes*, *Pasteurellaceae*, and *Butyricimonas* are inversely correlated with serum triglyceride and positively associated with serum high-density lipoprotein cholesterol, risk factors of hyperlipidemia or dyslipidemia in individuals [120–122].

3.1. Biochemical Mechanisms

Lactose-based prebiotics or their interaction with gut microbiota and probiotics control lipid level in bloodstream and tissue [123,124]. Different biochemical mechanisms have been reported in this context. The mechanisms are (a) suppression of lipogenic genes expression as well as the activities of lipogenic enzymes; (b) oxidation of fatty acids; (c) the binding of cholesterol

to the cell walls of probiotics and their assimilation; (d) enzymatic-conversions (de-conjugation, oxidation, and epimerization of hydroxyl groups at C3, C7, and C12, 7-dehydroxylation, esterification, and desulfatation) of bile acids; and (e) conversion of cholesterol to coprostanol and its defecation [125,126]. In the intestine, several consortia, such as *Bacteroides*, *Bifidobacteria*, *Clostridia*, *Lactobacillus*, *Listeria*, *Egghertella*, *Eubacteria*, *Peptostreptococcus*, *Ruminococcus*, *Fusobacteria*, *Peptococcus*, and *Pseudomonas* play a role in the above mentioned biochemical reactions [122,127,128]. The detailed mechanisms of controlling blood lipid level offered by lactose-based prebiotics and interaction with probiotics are presented in Figure 3 and subsequent sections.




Figure 3. Blood lipid controlling mechanisms, offered by lactose-based prebiotics and interaction with probiotics. SCFAs: Short-chain fatty acids; TMA: Trimethylamine; TMAO: Trimethylamine N-Oxide; PGC-1 α : Peroxisome proliferator-activated receptor gamma coactivator 1 α ; PPAR- γ : Peroxisome proliferator-activated receptor- γ ; AMPK: Adenosine monophosphate-activated protein kinase; FXR: Nuclear farnesoid X receptor; GLP-1: Glucagon-like peptide-1. (self-developed, figure compiled by authors based on Kumar et al., 2012 [129]; Anandharaj et al., 2014 [115]; Kasubuchi et al., 2015 [130]).

3.1.1. Suppression of Lipogenic Gene Expression and Activities of Lipogenic Enzymes

Short-chain fatty acids reduce the synthesis of cholesterol, fatty acid, triacylglycerol, and very-low-density lipoprotein via suppression of lipogenic gene expression. They also reduce the activities of lipogenic enzymes (acetyl-CoAcarboxylase, malic enzyme, fatty acid synthase, ATP citrate lyase, and glucose-6-phosphate dehydrogenase) in the liver [131]. Also in the liver, acetate is converted to acetyl CoA and acts as a lipogenic substrate for *de novo* lipogenesis, whereas propionate inhibits lipid synthesis [132,133]. A high level of circulating short-chain fatty acid is linked with reduced adipocyte lipolysis and adipogenesis [134]. Suppression of adipose tissue lipolysis supports the reduction of free-fatty acids in adipose tissue and the liver [135]. Furthermore, involvement of lactose-based prebiotics and probiotics suppress the activity of hydroxymethylglutarate CoA reductase as well

as endogenous cholesterol synthesis [136]. Short-chain fatty acids, mainly acetic acid, propionic acid, and butyric acid stimulate the synthesis of intestinal fasting-induced adipocyte factor, such as angiopoietin-like 4, by activating the peroxisome proliferator activated receptor γ in human colon adenocarcinoma cells [137,138] and subsequently inhibit fat storage. Probiotics increase the synthesis of angiopoietin-like 4, which leads to suppression of the activity of circulating lipoprotein lipase [139] and consequently reduces the storage of triglyceride in adipocyte and increases plasma triglyceride level [140,141]. Furthermore, angiopoietin-like 4 controls triglyceride deposition to adipocyte and diet-induced obesity [140–142].

3.1.2. Fatty Acid Oxidation

In muscle and liver tissue, butyrate enhances fatty acid oxidation by increasing the expression of peroxisome proliferator-activated receptor-gamma coactivator-1 α and phosphorylation of adenosine-monophosphate-activated kinase [143,144]. In brown adipose tissue, butyrate enhances thermogenesis and fatty acid oxidation by increasing the expression of peroxisome proliferator-activated receptor-gamma coactivator-1 α and mitochondrial uncoupling protein-1 [145,146]. Short-chain fatty acids influence bile acid receptors, such as membrane-bound G-protein coupled receptor TGR5 and nuclear farnesoid X receptor, and suppress fat accumulation in brown adipose tissue. Receptor TGR5 induces glucagon-like peptide-1 synthesis [147], whereas activation of receptor nuclear farnesoid X receptor reduces its activity [148]. Short-chain fatty acids reduce white adipose tissue mass and adipocyte size, and increase adipose-specific insulin signaling [149,150]. These promote a shift from lipogenesis to fatty acid oxidation [134,150]. Furthermore, short-chain fatty acids stimulate satiogenic hormone leptin secretion in adipocytes. Leptin increases fat oxidation in both muscle and liver tissue [151,152]. Gut microbiota increase the synthesis of triglycerides in the liver. Sterol response element binding protein 1c, carbohydrate response element binding protein, acetyl-CoA carboxylase, fatty acid synthase, and adenosine 5'-monophosphate-activated protein kinase influence lipogenesis through inducing glucose absorption and metabolism as well as insulin level [153]. Furthermore, intestinal microbiota produce trimethylamine N-oxide through the oxidation of trimethylamine by flavin monooxygenase in liver. Trimethylamine is a microbial product, derived from choline, phosphatidylcholine, and l-carnitine. Trimethylamine N-oxide reduces the risks of atherosclerosis and cardiometabolic through the perturbations of reverse cholesterol transport, metabolism of sterol and cholesterol, and/or compositions and quantities of bile acids [122].

3.1.3. Binding of Cholesterol to the Cell Walls of Probiotics and Their Assimilation

Lactose-based prebiotics endorse the growth of probiotics, and these offer an anti-hyperlipidemic effect to the host [115,126]. Cholesterol can bind with the cell membranes of probiotics [154,155]. Bile-salt hydrolase supports the incorporation of cholesterol into the cell membranes of probiotics [156,157]. In probiotic cell membranes, cholesterol accumulates in the regions of phospholipid tails, upper phospholipids, and polar heads of the membrane phospholipid bilayer [158,159]. It has been proven that growing cells, dead cells, and heat-killed probiotic cells are able to reduce cholesterol levels [158–160], and cholesterol removal is higher with growing cells than dead cells and heat-killed cells [161,162]. Assimilation of cholesterol into cellular membrane alters the fatty acid composition in cells. High-level accumulation of fatty acids (both unsaturated- and saturated-fatty acids) in cells leads to stronger membrane and cellular resistance, and subsequently increases the possibility of cell lysis [158,159].

3.1.4. Enzymatic-Conversions of Bile Acids

Lactose-based prebiotics promote the growth and activities of gut microbiota as well as probiotics [99]. Biotransformations of bile acids are involved with intestinal microorganisms, including probiotics during their enterohepatic circulation. Microbial bioconversions of bile acids

include (a) de-conjugation, (b) oxidation and epimerization of hydroxy groups at C3, C7, and C12, (c) $7\alpha/7\beta$ -dehydroxylation; and (d) esterification and desulfatation [127,128].

De-Conjugation

In the large intestine, certain facultative and anaerobic consortia, including probiotics (*Bacteroides*, *Lactobacillus*, Bifidobacteria, *Clostridia*, and *Listeria*) produce secondary bile acids (taurocholic acid, glycocholic acid, taurochenodeoxycholic acid, and glycochenodeoxycholic acid) from the pool of bile acids, such as cholic acid and chenodeoxycholic acid [163]. Intestinal microbes can alter the amount and type of secondary bile acids via nuclear farnesoid X receptor and TGR5 signaling. Bile-salt hydrolase from intestinal microbiota and probiotics hydrolyzes conjugated glycodeoxycholic acid and taurodeoxycholic acid in enterohepatic circulation and produces lower soluble de-conjugated bile acids (de-conjugation of glycol- and tauro-bile acids). A small fraction of these bile acids are absorbed by passive diffusion to the small intestine, and provide active transportation to the ileum and passive absorption to the colon [164]. As a consequence, they are eliminated via feces. Cholesterol is used to produce new bile acids to maintain homeostasis, which reduces the physiological cholesterol pool in the bloodstream [165]. In the intestine, some bacterial species use residual end products (carbon, nitrogen, and sulfur) of bile acids de-conjugation [128,166].

Oxidation and Epimerization of Hydroxy Groups at C3, C7, and C12

Gut microbiota catalyze oxidation/reduction of hydroxy groups at the 3-, 7-, and 12-carbons of bile acids with hydroxysteroid dehydrogenases. Epimerization of hydroxy groups occurs via stereospecific oxidation and, subsequently, stereospecific reduction with α -hydroxysteroid dehydrogenases and β -hydroxysteroid dehydrogenases, respectively [128,166]. The formation of stable oxo-bile acid intermediate is influenced by the catalytic activity of bacterial hydroxysteroid dehydrogenases, pH of environment and presence of pyridine nucleotides. Generally, both 3α -hydroxysteroid dehydrogenase and 3β -hydroxysteroid dehydrogenase are present in Firmicutes. However, 7α -hydroxysteroid dehydrogenases are present in *Eubacterium*, *Clostridia*, and *Bacteroides*, 7β -hydroxysteroid dehydrogenase is only present in Firmicutes. Furthermore, 12α -hydroxysteroid dehydrogenase and 12β -hydroxysteroid dehydrogenase have been discovered in different Firmicutes [128,164]. The epimerization of bile acids reduces the toxicity of hydrophobic chenodeoxycholic acid to intestinal microorganisms [164,167].

$7\alpha/7\beta$ -Dehydroxylation

Due to the unavailability of hydroxyl group after deconjugation of conjugated bile acids with bile-salt hydrolase, dehydroxylation of primary bile acids (cholic acid and chenodeoxycholic acids) takes place. Involvement of multiple genes in *bai* operon, removal of 7α -hydroxy or 7β -hydroxy group from primary bile acids, produces deoxycholic and lithocholic acids [166]. Activity of 7α -dehydroxylase has been identified in *Eubacterium* and *Clostridium* [128].

Esterification and Desulfatation

Intestinal microbiota produce esters of bile acids by esterification of C-24 carboxyl group of molecule associate with 3α -hydroxy group of the neighbor one in bile acids. Mixed fecal consortia are responsible for these bioconversions. Generally, *Bacteroides*, *Lactobacillus*, and *Eubacteria* participate in esterification of bile acids and *Clostridia*, *Fusobacteria*, *Peptococcus*, and *Pseudomonas* participate in desulfatation of bile acids [128,164].

3.1.5. Conversion of Cholesterol to Coprostanol and Its Defecation

Cholesterol levels in human individuals are balanced by lipid absorption, metabolic, and excretion processes. They are influenced by gut microflora, including probiotics [128,168]. In the intestine, lactose-based prebiotics stimulate the growth of probiotics [99] that convert cholesterol to coprostanol. Coprostanol is not water-soluble and is poorly absorbed in the gut [168], which promotes its direct defecation. Cholesterol dehydrogenase/isomerase produced by cholesterol oxidizing bacteria catalyzes

the transformation of cholesterol to coprostanol [169]. Probiotics, synthesized by intracellular- and extracellular-cholesterol reductase, convert cholesterol to coprostanol [159]. There are two major pathways for the conversion of cholesterol to coprostanol that have been reported. In the first pathway, direct reduction of the 5 to 6 double bond in cholesterol takes place. In the second pathway, primarily oxidation of the 3 β -hydroxy group and isomerization of double bond to form of 4-cholesten-3-one take place. Subsequently, coprostanone and then coprostanol are formed through the reduction pathway [128,170]. A decrease in the amount of cholesterol via enzymatic conversion and subsequently defecation leads to reduction of physiological cholesterol pool [127,128].

3.2. Clinical Investigations

Some clinical investigations have been performed with different types of lactose-based prebiotics to understand their anti-hyperlipidemic activities. Vogt et al., performed a semi-randomized crossover study with 18 healthy men (age 18 to 60 years) to understand the effects of lactulose on blood lipid profile and colonic short-chain fatty acids on hepatic lipid metabolism. The subjects were divided into two groups. The first group ($n = 9$) was randomly assigned to consume either L-rhamnose or lactulose 25 g day⁻¹. After a 3-month washout period, they enrolled in a D-glucose study period and among them seven subjects participated in a third study period. During study period three, they consumed the remaining lactulose or L-rhamnose. Subjects in the second group ($n = 9$) consumed D-glucose in their first study period and the day after the first study period, they were randomly assigned to consume either lactulose or L-rhamnose for a second study period. After a 6-month washout period, all subjects from second group and two from first group completed their final study period. It was reported that the sugar type did not affect fasting total cholesterol and triglyceride levels on either initial day or after 4 weeks, log-transformed values of fractional synthetic rates for triacylglycerol-fatty acids were significantly lower for the L-rhamnose-treated group and the lactulose-treated group than the D-glucose-treated group. In a similar way, absolute synthetic rates for triacylglycerol-fatty acids were lower for the L-rhamnose-treated group and the lactulose-treated group than the D-glucose-treated group [123]. Another double-blind, placebo controlled trial experiment was performed with 45 human subjects (male, $n = 16$, age 42.8 ± 12.1 years; female, $n = 29$, age 46.4 ± 11.8 years), who presented some risk factors of metabolic activities (fasting glucose 5.5 ± 0.8 mmol L⁻¹, total cholesterol 6.6 ± 1.2 mmol L⁻¹, high density lipid cholesterol 1.2 ± 0.2 mmol L⁻¹ and triglyceride 2.1 ± 0.9 mmol L⁻¹ in men; fasting glucose 5.2 ± 0.6 mmol L⁻¹, total cholesterol 6.1 ± 1.3 mmol L⁻¹, high density lipid cholesterol 1.5 ± 0.3 mmol L⁻¹ and triglyceride 1.3 ± 0.4 mmol L⁻¹ in women). Subjects were randomly assigned to a placebo group, a group treated with maltodextrin, and experimental, a group treated with galacto-oligosaccharide. Members of individual groups consumed respective products at 5.5 g day⁻¹ for 12 weeks, followed by a washout period of 4 weeks, before switching to another intervention for a final 12 weeks. It was reported that the concentrations of high density lipid cholesterol and low density lipid cholesterol in plasma were unchanged in members of both the placebo group and the experimental group, and the total concentration of cholesterol in plasma after the 12-week experiment was significantly lower in the galacto-oligosaccharide-treated group than the placebo group [124].

4. Controlling Blood Glucose Level

Of all different kinds of diabetes (type 1 diabetes, type 2 diabetes, gestational diabetes, latent autoimmune diabetes of adults, maturity onset diabetes of the young, and neonatal diabetes), type 2 diabetes is the most common, resulting in cardiovascular disease, retinopathy, nephropathy, neuropathy, hearing damage, skin damage, leg ulcers, and gangrene [171,172]. Insulin from islets of Langerhans in the pancreas plays a crucial role in the regulation of glucose homeostasis as well as blood glucose level [173,174]. Failure of response to insulin is the primary cause of type 2 diabetes. Excess accumulation of visceral fat causes chronic low-grade inflammation, regarded as a high level of macrophage infiltration. Furthermore, accumulation of visceral fat promotes insulin resistance and compensatory hyperinsulinemia [175,176]. In peripheral tissues, pro-inflammatory adipokines

hinder insulin signaling and may cause insulin resistance [177–179]. The risk factors for type 2 diabetes include (a) obesity; (b) age; (c) sex; (d) heredity; (e) hypertension; (f) Alzheimer’s disease; (g) smoking; and (h) sedentary lifestyle [41,130,177,180,181]. Gut microbiota have direct correlation with both type 1 diabetes and type 2 diabetes. Type 2 diabetes is associated with the declination of *Roseburia*, *Faecalibacteria*, *Clostridia*, *Betaproteobacteria*, and *Eubacteria*, and an increase of several pathogens, such as *Bacteroides*, *Akkermansia*, *Desulfovibrio*, and some pathogenic *Clostridia* [120,182]. Type 1 diabetes is associated with the reduction of Firmicutes, *Lactobacillus*, Bifidobacteria, *Blautia*, *Eubacteria*, and *Prevotella*, and an increase of *Bacteroidetes*, pathogenic *Clostridia*, and *Veillonella* [182].

4.1. Biochemical Mechanisms

Research has proven that lactose-based prebiotics reduce long-standing high levels of blood glucose (hyperglycemia) in hosts [183,184]. The mechanisms include: (a) Controlling the synthesis and activities of gut hormones by synthesis of gut hormones plasma peptide-YY, glucagon-like peptide-1 and glucagon-like peptide-2; (b) altering glucose assimilation and metabolism through protecting the liver from inflammation, control of gluconeogenesis, synthesis of angiopoietin-like 4 and activation of peroxisome proliferator-activated receptor γ ; (c) controlling the synthesis and activities of pro-inflammatory and anti-inflammatory cytokines through immunomodulation; (d) reducing oxidative stress through suppressing inflammation and enhancing intestinal barrier, different antioxidative mechanisms, such as reactive oxygen species scavenging, metal ion chelation, down-regulated ascorbate autoxidation, and synthesis of antioxidant enzymes and molecules; and (e) producing amino acids [41,177,180,185]. Involvement of several beneficial intestinal microbes, such as *Lactobacillus*, Bifidobacteria, *Propionibacteria*, *Clostridia*, *Akkermansia*, and *Faecalibacteria* provide protection from diabetes [186,187]. The detailed mechanisms regarding reduction of hyperglycemia, offered by lactose-based prebiotics and interaction with probiotics are presented in Figure 4 and subsequent sections.




Figure 4. Hyperglycemia controlling mechanisms, offered by lactose-based prebiotics and interaction with probiotics. TNF- α : Tumor necrosis factor- α ; PPAR- γ : Peroxisome proliferator-activated receptor- γ ; AMPK: Adenosine monophosphate-activated protein kinase; GLP-1: Glucagon-like peptide-1; GLP-2: Glucagon-like peptide-2; NF- κ B: Nuclear factor- κ B. (self-developed, figure compiled by authors based on Kasubuchi et al., 2015 [130]; Janssen and Kersten, 2015 [181]; Sáez-Lara et al., 2016 [188]).

4.1.1. Control the Synthesis and Activities of Gut Hormones

In the intestine, lactose-based prebiotics are converted to short-chain fatty acids (butyric acid, acetic acid, and propionic acid) and lactic acid by probiotics [99]. They increase the synthesis of gut hormones plasma peptide-YY, glucagon-like peptide-1 and glucagon-like peptide-2 from entero-endocrine L cells through the activation of G-protein coupled receptors [130,189]. Glucagon-like peptide-1 inhibits glucagon secretion and impedes gluconeogenesis in the liver. Furthermore, it improves B-cell growth and insulin sensitivity in the pancreas [177]. Plasma peptide-YY inhibits gastric emptying and gastrointestinal motility, and promotes glucose uptake in muscle and adipose tissue [190,191]. It has been proven that propionate increases postprandial plasma peptide-YY and glucagon-like peptide-1 concentrations [153]. Butyrate improves insulin sensitivity [146] and acetate improves glucose tolerance [192]. Furthermore, it has been reported that probiotics increase the activities of gut hormone glucagon-like peptide-2, and decrease intestinal permeability, hepatic inflammation, and oxidative stress associated with the risk of diabetes [193].

4.1.2. Alternation of Glucose Assimilation and Metabolism

Lactose-based prebiotics associate with probiotics maintain glucose homeostasis. In the body, glucose homeostasis is maintained by glucose assimilation and metabolism. Symbiosis of lactose-based prebiotics and probiotics reduces immune dysfunction (both adaptive- and innate-immune dysfunctions) by suppressing hepatic inflammation and controlling several metabolic pathways of glucose metabolism in the liver. Suppression of immune dysfunction is associated with alternations of the activities of Toll-like receptors, present in parenchymal and non-parenchymal cells in the liver. The alternation of the activities of Toll-like receptors controls the synthesis and activities of several pro-inflammatory immune cells (interleukin 6, interleukin 18, and other pro-inflammatory mediators) in effector hepatic stellate cells [194,195]. Butyrate and propionate reduce gluconeogenesis in the liver through the activation of hepatic adenosine monophosphate-activated protein kinase pathway, which decreases the gene expressions of gluconeogenic enzymes, such as glucose 6-phosphatase and phosphoenolpyruvate carboxykinase [144,150], associated with affecting gut-brain neural circuitry [196,197]. Short-chain fatty acids (butyric acid, acetic acid, and propionic acid) promote the synthesis of angiopoietin-like 4, which improves glucose tolerance and decreases blood glucose [198]. Activity of angiopoietin-like 4 is induced by activation of peroxisome proliferator-activated receptor γ . Transcription factor peroxisome proliferator-activated receptor γ improves adiponectin secretion from mature adipocytes, which activates glucose transporter GLUT4 in skeletal muscle [199,200] and subsequently inhibits gluconeogenesis in the liver [201]. This process leads to improved insulin sensitivity in skeletal muscle cells and the liver. Furthermore, probiotics may alter glucose assimilation and metabolism by delaying or inhibiting glucose absorption in the intestine, increasing bioavailability of gliclazide [202] and changing the function of autonomic nervous system [203]. Gut microbiota control glucose absorption and metabolism, and subsequently lipogenesis in the liver through regulating sterol response element binding protein 1c, carbohydrate response element binding protein, acetyl-CoA carboxylase, fatty acid synthase, and adenosine 5'-monophosphate-activated protein kinase [204]. Intestinal microbiota influence the synthesis and concentrations of bile acids, which control glucose homeostasis through the activation of the nuclear farnesoid X receptor and membrane-bound G-protein coupled receptors [205]. In the ileum, activation of nuclear farnesoid X receptor controls the synthesis of fibroblast growth factor-19, which affects glucose tolerance [206]. In the pancreas, activation of nuclear farnesoid X receptor controls insulin transport and secretion [207]. In the liver, activation of nuclear farnesoid X receptor improves insulin sensitivity [208]. In the ileum, activation of G-protein coupled receptors control the production of glucagon-like peptide-1, which plays a role in the maintenance of glucose homeostasis [177].

4.1.3. Immunomodulation

Alterations of hepatic natural killer T-cell activity might lead to relative over-production of pro-inflammatory cytokines, which is the cause of systemic inflammation and insulin resistance [177,209]. The pro-inflammatory tumor necrosis factor- α /inhibitor of nuclear factor kappa-B kinase subunit beta signaling pathway mediates insulin resistance [210,211]. Activation of inhibitor of nuclear factor kappa-B kinase subunit beta causes both hepatic and systematic insulin resistance [212]. Lactose-based prebiotics are converted to short-chain fatty acids and promote the growth of probiotics, and these offer an anti-diabetic effect via prevention of inflammation and immunomodulation. Symbiosis of lactose-based prebiotics and probiotics reduces gut permeability as well as pathogenic translocation from the intestine to mesenteric adipose tissue and blood. Consequently, these reduce systemic inflammation [213,214]. Short-chain fatty acids offer anti-inflammatory effects by inhibiting the activation of nuclear factor kappa-light-chain-enhancer of activated B cells (a transcriptional factor) [215,216] as well as suppressing proinflammatory items, such as high-sensitivity C-reactive protein, tumor necrosis factor α , interferon γ , interleukin 1β , and interleukin 6 [217–219]. Short-chain fatty acids suppress the activities of tumor necrosis factor α and nuclear factor kappa-light-chain-enhancer of activated B cells by facilitating PGE2 levels and cyclo-oxygenase-2 activities by inhibiting histone deacetylase [216,220]. Furthermore, butyrate decreases the expression of chemokine MCP-1 [217]. Butyrate inhibits the activity of T cells by down-regulating the expression of intracellular cell adhesion molecule-1 through the suppression of tumor necrosis factor α and interleukin 1β in human umbilical vein endothelial cells [221,222], and lymphocyte function-associated antigen-3 in monocytes [223]. Several intestinal bacteria induce the formation of inflammatory T cells (T helper 1 cell and T helper 17 cell) as well as synthesis of interleukin 1, interleukin 6, and interleukin 12. Furthermore, commensal microbiota stimulate the expression of FOXP3 (scurfin) in CD4 + T cells and differentiation of T_{reg} cells, those lead to the production of secretory immunoglobulin A [224].

4.1.4. Reduction of Oxidative Stress

Lactose-based prebiotics are converted to lactic acid, short-chain fatty acids and promote the growth of probiotics. Short-chain fatty acids associated with probiotics may reduce oxidative stress (over production of reactive oxygen species and reactive nitrogen species), caused by inflammation in hepatic cells and the pancreas, and may control glucose level in the blood [189,225,226]. Short-chain fatty acids promote antioxidation and decrease oxidative stress in diabetic patients [227]. Butyrate inhibits the activity of xanthine dehydrogenase and increases the synthesis of glutathione, an antioxidant. Furthermore, they suppress purine catabolism as the formation of uric acid and reactive oxygen species [69]. Prebiotic-derived short-chain fatty acids suppress the synthesis and activities of pro-inflammatory cytokines, chemokines, and pro-inflammatory mediators, generated during oxidative stress [218]. Probiotics involved in several biochemical mechanisms, such as protection from inflammation in the gut and destruction of tight junctions, reactive oxygen species scavenging, metal ion chelation, and down-regulated ascorbate autoxidation [225,226]. Probiotics suppress the inflammation by reducing translocation of pathogens through enhancing intestinal barrier by (a) integration of gut epithelium cells through the synthesis of short-chain fatty acids [46,47], bacteriocins [48,49], antimicrobial peptides [50,51], mucin [52,53], collagen, fibronectin or fibrinogen [54–56], bacterial s-layer protein [57–59], and lectin-like protein [60,61]; (b) superiority of probiotics to adhere to mucosal surface; and (c) improvement of intestinal mucosal barrier defending activity through the development of a mucus layer [53,62,63] and integration of tight junction and alternation of cell surface proteins [64–66]. The pattern recognition toll-like receptors in gut epithelial layer recognize probiotic signals and bind them with lectin-like proteins. Subsequently, nuclear factor kappa B deactivates the expression of pro-inflammatory cytokine, such as tumor necrosis factor α and immune regulatory cytokine interferon γ [228]. Antioxidative enzymes, such as superoxide dismutase, catalase, glutathione peroxidase type 2, and peroxiredoxins from probiotics play role in

reducing oxidative stress. Furthermore, probiotics inhibit oxidative stress through the synthesis of non-enzymatic antioxidants, such as glutathione, folate, and exopolysaccharide [225,226].

4.1.5. Bioavailability of Amino Acids

In the gastrointestinal tract, lactose-based prebiotics endorse the growth of probiotics and maintain equilibrium of intestinal microbiota. In the intestine, proteins are hydrolyzed to peptides and amino acids by host- and bacterial-peptidases and proteases, and both gut bacteria and the host further utilize synthesized peptides and amino acids. Synthesized amino acids are incorporated to host- and bacterial-cells as building block of protein. The preferential amino acids for intestinal microbiota are lysine, glycine, arginine, valine, isoleucine, and leucine [229] and generate a complex mixture of metabolic end products, i.e., lactic acid, short-chain fatty acids (butyric acid, acetic acid, and propionic acid), branched-chain fatty acids (isobutyric acid, valeric acid, and isovaleric acid), and ammonia. It has been reported that undigested proteins and amino acids in the colon may serve as an additional substrate for production of short-chain fatty acids [230,231]. Furthermore, several amino acids produced by protein fermentation can serve as precursors for the synthesis of short-chain fatty acids [232]. It has been reported that amino acids play a role in the maintenance of glucose homeostasis as well as secretion of glucagon and insulin [233]. However, higher concentrations of branched-chain amino acids in blood are associated with risks of developing type 2 diabetes [234], leucine, alanine, glutamine, glutamate, and arginine stimulate β -cell activity and insulin secretion [235].

4.2. Clinical Investigations

In this context, some clinical investigations have been performed with different lactose-based prebiotics. Mooradian et al., performed an experiment with 48 male subjects, (mean age 52.4 ± 1.8 years), who suffered with diabetes mellitus and, among them, 14 subjects were treated with insulin therapy. Mean fasting plasma glucose was 200 ± 14.4 mg dL⁻¹ and mean glycosylated haemoglobin was $10.3 \pm 0.33\%$. Thirteen diabetic patients had clinically significant renal disease (proteinuria greater than a trace or creatinine greater than 1.3). For all patients, serum creatinine level was not greater than 2.0. Results were compared with 13 males, aged between 27 to 62 years, had normal fasting plasma glucose, and glycosylated haemoglobin levels (considered as the control). Subjects consumed an oral sugar solution (20 g of sucrose, 1 g of L-rhamnose, 20 g of lactose and 5 g of lactulose were added in 7.5 cc Cephalac in a volume of 110 cc) within a period of 3 min followed by the consumption of an equal volume of water after an overnight fast. Patients maintained fasting for additional 2 h and subsequently consumed water ad libitum to produce a sufficient amount of urine. It was reported that lactulose excretions were significantly low in control subjects compared to diabetic patients. Similarly, a urinary excretion of L-rhamnose was significantly low in normal subjects compared to diabetic patients. However, subjects with type 1 diabetes (insulin-dependent diabetes) had significantly higher urinary lactulose excretion compared to type 2 diabetes (non-insulin-dependent diabetes), the urinary excretion of L-rhamnose and L/R ratio were not significantly higher in type 1 diabetic subjects [183]. In another short-term crossover clinical trial, the effects of lactulose supplementation in biscuits on day-time glucose, insulin, and amino acid concentrations were studied with 10 obese patients. All patients had normal or high-normal fasting blood glucose (average fasting blood glucose was 5.2 ± 0.6 mmol L⁻¹), but only two subjects had normal glucose tolerance in response to oral glucose administration. Four subjects were classified as impaired glucose tolerance and four subjects had diabetes mellitus. All patients received three biscuits at breakfast, four biscuits during lunch and four biscuits during evening meal. The recipe of lactulose-fortified biscuit was 10 g of dietary fiber, 2 g of raw fiber and 8.2 g of lactulose. It was reported that average day-time glucose and insulin level were significantly decreased due to lactulose supplemental biscuit intake [184].

5. Conclusions, Remarks and Future Prospects

Prebiotics galacto-oligosaccharide, lactosucrose, tagatose, lactulose, lactitol, and bionic acid are produced through different enzymatic- and microbial-bioconversions of lactose. They have unique biological activities and the Federal Food and Drug Administration (FDA) has declared them 'safe'. However, whereas lactose-based prebiotics are stable in the upper intestinal tract, they are converted to lactic acid and short chain fatty acids (acetic acid, propionic acid and butyric acid), and gases (carbon dioxide, methane, hydrogen) in presence of gut microbiota. Physicians frequently recommend consumption of lactose-based prebiotics with fruit juices and dairy products, and in some cases, with probiotics to individuals of all ages. When lactose-based prebiotics are consumed alone, their biological activities are expressed via interaction with already existing gut microbiota. Consumption of lactose-based prebiotics with probiotics offers some extra advantages due to the symbiotic activity. Results of several clinical investigations indicate that galacto-oligosaccharide can reduce the risks of osteoporosis and hyperlipidemia. Lactulose can reduce the risks of osteoporosis, hyperlipidemia, and hyperglycemia.

However, although lactose-based prebiotics are confirmed as safe, over consumption of them can cause osmotic diarrhea, dehydration, abdominal pain, and vomiting. Doses of galacto-oligosaccharide and lactulose are adjusted to 7.5 to 15 g day⁻¹ for 7 to 21 days and 3 to 20 g day⁻¹ for 14 to 28 days, respectively to ensure 2 to 4 bowel movements per day [236]. Nevertheless, probiotics are considered as 'Generally Regarded As Safe' (GRAS), in some cases, probiotics offer negative outcomes. In children with a short bowel syndrome, over production of toxic metabolites, such as D-lactate can be related with high consumption of probiotics along with lactose-based prebiotics or normal diet [237]. Predominance of *Bacillus subtilis* in infant formula is responsible for allergic and autoimmune diseases. In patients with short bowel syndrome, intake of *Lactobacillus* GG may create infection, such as endocarditis and bacteremia due to their translocation from the digestive tract to extra-intestinal sites. Furthermore, fungemia, due to contamination with *Saccharomyces* spp. in central catheters in patients who had jejunostomy, cancer, multiple comorbidities, and were immunocompromised, has been reported on several occasions [238,239]. However, whereas some *Bacillus* spp., such as *Bacillus subtilis*, *Bacillus coagulans*, *Bacillus cereus*, *Bacillus clausii*, and *Bacillus licheniformis* are used as a probiotic, food fortification, and food-grade biomolecule production, their applications as probiotics are an issue of debate from a safety point of view [240]. However, the optimum dose of each probiotic strain and their durability are unknown. Commercially available probiotic formulations generally have 10⁶–10¹² colony forming units of probiotics day⁻¹ [241]. Random consumption of unknown or non-recommended probiotics deplete the equilibrium of microbial community in the intestine and provide antibiotic resistance to unfavorable consortia in the gut due to antibiotic resistance plasmids transfer to commensal bacteria from probiotics *Lactobacillus* and Bifidobacteria. [242]. However, consumption of several or unknown probiotics may enhance nonspecific immune responses, and their effect on adaptive cellular and humoral immune responses are potentially significant [243]. Up to now, a substantial number of investigations have been performed with monoculture of lactic acid bacteria, such as *Lactobacillus*, Bifidobacteria [244], and commercial mixed culture VSL#3 [245]. Few studies have been published about other probiotics, such as *Enterococcus*, *Pediococcus*, *Leuconostoc*, *Lactococcus*, *Streptococcus*, [246] and other commercial lactic acid bacterial culture, such as Probio-Tec[®], Culturelle[®], Actimel[®] (DanActive), Activia[®] and Yakult[®] [245]. Information about several non-lactic acid probiotic bacteria, including *Bacillus*, *Clostridia*, *Propionibacteria*, and *Escherichia coli* Nissle 1917 is limited [246].

Although some clinical investigations have been performed with lactose-based prebiotics, mainly galacto-oligosaccharide and lactulose in this context, many more judicious investigations are required with human models to demonstrate their mechanisms, safety, efficiencies, and limitations. Furthermore, clinical investigations with other lactose-based prebiotics, such as lactitol and lactosucrose are needed to understand their effectiveness against osteoporosis, hyperlipidemia, and hyperglycemia. As biochemical activities of lactose-based prebiotics are expressed in a better way in the presence of probiotics, future challenges shall be to find out suitable strains, the introduction of the newer

generation of probiotics, identify their metabolic pathways, synthesized metabolites, and their biochemical importance. Several clinical investigations have argued that, due to the wide range of microbial diversity in terms of activity and associate biochemical mechanisms among similar genus and even within species, it is not worth generalizing and comparing the potentialities of probiotics. Their application is dose-, age-, and situation-dependent. Therefore, a great emphasis is needed on the accumulation of knowledge about exact genus and specie of both lactic acid- and non-lactic acid bacteria by high throughput sequencing and advanced bioinformatics. To understand their activities, more specialized in vitro and in vivo investigations are necessary. Furthermore, systematic and judicious investigations are a prerequisite to find out their optimum dose, mode of administration, and associated safety.

Direct disposal of whey in aquatic systems is forbidden due to presence of high concentration of lactose in whey. In the context of 'Waste valorization', production of different types of prebiotics from whey or de-proteinated whey via enzymatic-biotransformation as well as microbial fermentation processes may be a unique approach, rather than the direct disposal of whey into the aquatic system. In the cutting-edge area in biotechnology, this approach can be a two-fold solution to the questions related to the biotechnological economy and recycling strategy. Furthermore, it is expected that this review will receive the attention of medical practitioners, food, and nutrition research communities.

Author Contributions: A.N. was involved to summarize the information, cross-check the findings related with clinical trials from downloaded articles, develop the figures, and to write the whole manuscript. A.C. and K.K. were involved to download the articles from Web of Science and Google Scholar. M.A.M., I.G. and K.P.H. were involved to analyze and summarize the results of clinical trials, and develop the figures and table. A.K. and G.V. were involved to check the whole manuscript.

Funding: The first author acknowledges the Hungarian State Board Post-doctoral Research Fellowship and the project 'Széchenyi 2020' (grant agreement no. EFOP-3.6.1-16-2016-00015). The reported work is a part of a European Union project (grant agreement no. EFOP-3.6.3-VEKOP-16-2017-00005).

Acknowledgments: Authors acknowledge Szent István University, Doctoral school of Food Science, Hungary.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Saad, N.; Delattre, C.; Urdaci, M.C.; Schmitter, J.-M.; Bressollier, P. An overview of the last advances in probiotic and prebiotic field. *LWT Food Sci. Technol.* **2013**, *50*, 1–16. [[CrossRef](#)]
2. Wang, Y. Prebiotics: Present and future in food science and technology. *Food Res. Int.* **2009**, *42*, 8–12. [[CrossRef](#)]
3. Roberfroid, M. Prebiotics: The Concept Revisited. *J. Nutr.* **2007**, *137*, 830S–837S. [[CrossRef](#)] [[PubMed](#)]
4. Tadesse, S. Probiotics, Prebiotics and Synbiotics as Functional Food Ingredients: Production, Health Benefits and Safety. *J. Biol. Act. Prod. Nat.* **2012**, *2*, 124–134. [[CrossRef](#)]
5. Al-Sheraji, S.H.; Ismail, A.; Manap, M.Y.; Mustafa, S.; Yusof, R.M.; Hassan, F.A. Prebiotics as functional foods: A review. *J. Funct. Foods* **2013**, *5*, 1542–1553. [[CrossRef](#)]
6. Markowiak, P.; Slizewska, K. Effects of Probiotics, Prebiotics, and Synbiotics on Human Health. *Nutrients* **2017**, *9*, 1021. [[CrossRef](#)]
7. Nath, A.; Verasztó, B.; Basak, S.; Koris, A.; Kovács, Z.; Vatai, G. Synthesis of Lactose-Derived Nutraceuticals from Dairy Waste Whey—A Review. *Food Bioprocess Technol.* **2016**, *9*, 16–48. [[CrossRef](#)]
8. Nath, A.; Mondal, S.; Csighy, A.; Molnár, M.A.; Páztorné-Huszár, K.; Kovács, Z.; Koris, A.; Vatai, G. Biochemical activities of lactose-derived prebiotics—A review. *Acta Aliment.* **2017**, *46*, 449–456. [[CrossRef](#)]
9. Company, G.N. *Generally Recognized as Safe Notification for Galacto-Oligosaccharide*; GTC Nutrition Company: Golden, CO, USA, 2009.
10. Vera, C.; Illanes, A. Lactose-Derived Nondigestible Oligosaccharides and Other High Added-Value Products. In *Lactose-Derived Prebiotics—A Process Prospective*, 1st ed.; Illanes, A., Guerrero, C., Vera, C., Wilson, L., Conejeros, R., Scott, F., Eds.; Elsevier: San Diego, CA, USA, 2016; pp. 87–110, ISBN 978-0-12-802724-0.
11. Shiby, V.; Mishra, H. Fermented milks and milk products as functional foods—A review. *Crit. Rev. Food Sci. Nutr.* **2013**, *53*, 482–496. [[CrossRef](#)]

12. Lin, C.S.; Chang, C.J.; Lu, C.C.; Martel, J.; Ojcius, D.M.; Ko, Y.F.; Young, J.D.; Lai, H.C. Impact of the gut microbiota, prebiotics, and probiotics on human health and disease. *Biomed. J.* **2014**, *37*, 259–268.
13. Sommer, F.; Bäckhed, F. The gut microbiota—masters of host development and physiology. *Nat. Rev. Microbiol.* **2013**, *11*, 227–238. [[CrossRef](#)] [[PubMed](#)]
14. Hayashi, H.; Takahashi, R.; Nishi, T.; Sakamoto, M.; Benno, Y. Molecular analysis of jejunal, ileal, caecal and recto-sigmoidal human colonic microbiota using 16S rRNA gene libraries and terminal restriction fragment length polymorphism. *J. Med. Microbiol.* **2005**, *54*, 1093–1101. [[CrossRef](#)]
15. Hayashi, H.; Sakamoto, M.; Benno, Y. Phylogenetic analysis of the human gut microbiota using 16S rDNA clone libraries and strictly anaerobic culture-based methods. *Microbiol. Immunol.* **2002**, *46*, 535–548. [[CrossRef](#)] [[PubMed](#)]
16. Wong, J.M.; de Souza, R.; Kendall, C.W.; Emam, A.; Jenkins, D.J. Colonic health: Fermentation and short chain fatty acids. *J. Clin. Gastroenterol.* **2006**, *40*, 235–243. [[CrossRef](#)] [[PubMed](#)]
17. Goh, Y.J.; Klaenhammer, T.R. Genetic mechanisms of prebiotic oligosaccharide metabolism in probiotic microbes. *Annu. Rev. Food Sci. Technol.* **2015**, *6*, 137–156. [[CrossRef](#)]
18. Fooks, L.J.; Fuller, R.; Gibson, G.R. Prebiotics, probiotics and human gut microbiology. *Int. Dairy J.* **1999**, *9*, 53–61. [[CrossRef](#)]
19. Valdes, A.M.; Walter, J.; Segal, E.; Spector, T.D. Role of the gut microbiota in nutrition and health. *BMJ* **2018**, *361*, k2179. [[CrossRef](#)] [[PubMed](#)]
20. Roberfroid, M.B. Prebiotics and probiotics: Are they functional foods? *Am. J. Clin. Nutr.* **2000**, *71*, 1682S–1687S. [[CrossRef](#)] [[PubMed](#)]
21. Thongaram, T.; Hoeflinger, J.L.; Chow, J.; Miller, M.J. Prebiotic Galactooligosaccharide Metabolism by Probiotic Lactobacilli and Bifidobacteria. *J. Agric. Food Chem.* **2017**, *65*, 4184–4192. [[CrossRef](#)] [[PubMed](#)]
22. Rizzoli, R. Nutrition: Its role in bone health. *Best. Pract. Res. Clin. Endocrinol. MeTab.* **2008**, *22*, 813–829. [[CrossRef](#)]
23. Krela-Kaźmierczak, I.; Szymczak, A.; Łykowska-Szuber, L.; Eder, P.; Linke, K. Osteoporosis in Gastrointestinal Diseases. *Adv. Clin. Exp. Med.* **2016**, *25*, 185–190. [[CrossRef](#)] [[PubMed](#)]
24. Heaney, R.P. Nutrition and risk for osteoporosis. In *Osteoporosis*, 2nd ed.; Marcus, R., Feldman, D., Kelsey, J., Eds.; Elsevier: Omaha, NE, USA, 2001; Volume 1, pp. 669–700, ISBN 978-0-12-470862-4.
25. Di Stefano, M.; Veneto, G.; Malservisi, S.; Corazza, G.R. Small intestine bacterial overgrowth and metabolic bone disease. *Dig. Dis. Sci.* **2001**, *46*, 1077–1082. [[CrossRef](#)] [[PubMed](#)]
26. Wang, J.; Wang, Y.; Gao, W.; Wang, B.; Zhao, H.; Zeng, Y.; Ji, Y.; Hao, D. Diversity analysis of gut microbiota in osteoporosis and osteopenia patients. *PeerJ* **2017**, *5*, e3450. [[CrossRef](#)] [[PubMed](#)]
27. van den Heuvel, E.G.; Schaafsma, G.; Muys, T.; van Dokkum, W. Nondigestible oligosaccharides do not interfere with calcium and nonheme-iron absorption in young, healthy men. *Am. J. Clin. Nutr.* **1998**, *67*, 445–451. [[CrossRef](#)] [[PubMed](#)]
28. van den Heuvel, E.G.; Schoterman, M.H.; Muijs, T. Transgalactooligosaccharides stimulate calcium absorption in postmenopausal women. *J. Nutr.* **2000**, *130*, 2938–2942. [[CrossRef](#)] [[PubMed](#)]
29. Seki, N.; Hamano, H.; Iiyama, Y.; Asano, Y.; Kokubo, S.; Yamauchi, K.; Tamura, Y.; Uenishi, K.; Kudou, H. Effect of lactulose on calcium and magnesium absorption: A study using stable isotopes in adult men. *J. Nutr. Sci. Vitaminol.* **2007**, *53*, 5–12. [[CrossRef](#)] [[PubMed](#)]
30. Bongers, A.; van den Heuvel, E.G.H.M. Prebiotics and the Bioavailability of Minerals and Trace Elements. *Food Rev. Int.* **2003**, *19*, 397–422. [[CrossRef](#)]
31. Scholz-Ahrens, K.E.; Ade, P.; Marten, B.; Weber, P.; Timm, W.; Açil, Y.; Glüer, C.C.; Schrezenmeir, J. Prebiotics, probiotics, and synbiotics affect mineral absorption, bone mineral content, and bone structure. *J. Nutr.* **2007**, *137*, 838S–846S. [[CrossRef](#)] [[PubMed](#)]
32. Whisner, C.M.; Castillo, L.F. Prebiotics, Bone and Mineral Metabolism. *Calcif. Tissue Int.* **2018**, *102*, 443–479. [[CrossRef](#)]
33. McCabe, L.; Britton, R.A.; Parameswaran, N. Prebiotic and Probiotic Regulation of Bone Health: Role of the Intestine and its Microbiome. *Curr. Osteoporos. Rep.* **2015**, *13*, 363–371. [[CrossRef](#)]
34. Weaver, C.M. Diet, gut microbiome, and bone health. *Curr. Osteoporos. Rep.* **2015**, *13*, 125–130. [[CrossRef](#)] [[PubMed](#)]
35. Trinidad, T.P.; Wolever, T.M.S.; Thompson, L.U. Interactive effects of calcium and short chain fatty acids on absorption in the distal colon of man. *Nutr. Res.* **1993**, *13*, 417–425. [[CrossRef](#)]

36. Strause, L.; Saltman, P. Role of Manganese in Bone Metabolism. In *Nutritional Bioavailability of Manganese*; Kies, C., Ed.; ACS Symposium Series; American Chemical Society: Washington, DC, USA, 1987; Volume 354, pp. 45–55, ISBN 13-978-0-84-121433-0.
37. Wallach, S. Relation of magnesium to osteoporosis and calcium urolithiasis. *Magnes. Trace Elem.* **1991–1992**, *10*, 281–286.
38. Nielsen, F.H. Studies on the relationship between boron and magnesium which possibly affects the formation and maintenance of bones. *Magnes. Trace Elem.* **1990**, *9*, 61–69. [[CrossRef](#)]
39. Lowe, N.M.; Lowe, N.M.; Fraser, W.D.; Jackson, M.J. Is there a potential therapeutic value of copper and zinc for osteoporosis? *Proc. Nutr. Soc.* **2002**, *61*, 181–185. [[CrossRef](#)] [[PubMed](#)]
40. Scholz-Ahrens, K.E.; Schaafsma, G.; van den Heuvel, E.G.; Schrezenmeier, J. Effects of prebiotics on mineral metabolism. *Am. J. Clin. Nutr.* **2001**, *73*, 459S–464S. [[CrossRef](#)]
41. den Besten, G.; van Eunen, K.; Groen, A.K.; Venema, K.; Reijngoud, D.J.; Bakker, B.M. The role of short-chain fatty acids in the interplay between diet, gut microbiota, and host energy metabolism. *J. Lipid Res.* **2013**, *54*, 2325–2340. [[CrossRef](#)] [[PubMed](#)]
42. Linsalata, M.; Russo, F.; Berloco, P.; Valentini, A.M.; Caruso, M.L.; De Simone, C.; Barone, M.; Polimeno, L.; Di Leo, A. Effects of probiotic bacteria (VSL#3) on the polyamine biosynthesis and cell proliferation of normal colonic mucosa of rats. *In Vivo* **2005**, *19*, 989–995. [[PubMed](#)]
43. Löser, C.; Eisel, A.; Harms, D.; Fölsch, U.R. Dietary polyamines are essential luminal growth factors for small intestinal and colonic mucosal growth and development. *Gut* **1999**, *44*, 12–16. [[CrossRef](#)]
44. Nath, A.; Haktanirlar, G.; Varga, Á.; Molnár, M.A.; Albert, K.; Galambos, I.; Koris, A.; Vatai, G. Biological activities of Lactose-derived Prebiotics and Symbiotic with Probiotics on Gastrointestinal system. *Medicina* **2018**, *54*, 18. [[CrossRef](#)]
45. Balakrishnan, M.; Floch, M.H. Prebiotics, probiotics and digestive health. *Curr. Opin. Clin. Nutr. Metab. Care* **2012**, *15*, 580–585. [[CrossRef](#)] [[PubMed](#)]
46. Terracciano, J.S.; Schreurs, W.J.; Kashket, E.R. Membrane H⁺ conductance of *Clostridium thermoaceticum* and *Clostridium acetobutylicum*: Evidence for electrogenic Na⁺/H⁺ antiport in *Clostridium thermoaceticum*. *Appl. Environ. Microbiol.* **1987**, *53*, 782–786. [[PubMed](#)]
47. Diez-Gonzalez, F.; Russell, J.B. The ability of *Escherichia coli* O157:H7 to decrease its intracellular pH and resist the toxicity of acetic acid. *Microbiology* **1997**, *143*, 1175–1180. [[CrossRef](#)] [[PubMed](#)]
48. Nes, I.F.; Yoon, S.-S.; Diep, D.B. Ribosomally Synthesized Antimicrobial Peptides (*Bacteriocins*) in Lactic Acid Bacteria. *Food Sci. Biotechnol.* **2007**, *16*, 675–690.
49. van Kraaij, C.; de Vos, W.M.; Siezen, R.J.; Kuipers, O.P. Lantibiotics: Biosynthesis, mode of action and applications. *Nat. Prod. Rep.* **1999**, *16*, 575–587. [[CrossRef](#)] [[PubMed](#)]
50. Ohland, C.L.; Macnaughton, W.K. Probiotic bacteria and intestinal epithelial barrier function. *Am. J. Physiol. Gastrointest. Liver Physiol.* **2010**, *298*, G807–G819. [[CrossRef](#)] [[PubMed](#)]
51. Karczewski, J.; Troost, F.J.; Konings, I.; Dekker, J.; Kleerebezem, M.; Brummer, R.J.; Wells, J.M. Regulation of human epithelial tight junction proteins by *Lactobacillus plantarum* in vivo and protective effects on the epithelial barrier. *Am. J. Physiol. Gastrointest. Liver Physiol.* **2010**, *298*, G851–G859. [[CrossRef](#)]
52. Jung, T.H.; Park, J.H.; Jeon, W.M.; Han, K.S. Butyrate modulates bacterial adherence on LS174T human colorectal cells by stimulating mucin secretion and MAPK signaling pathway. *Nutr. Res. Pract.* **2015**, *9*, 343–349. [[CrossRef](#)] [[PubMed](#)]
53. Burger-van Paassen, N.; Vincent, A.; Puiman, P.J.; van der Sluis, M.; Bouma, J.; Boehm, G.; van Goudoever, J.B.; van Seuningen, I.; Renes, I.B. The regulation of intestinal mucin MUC2 expression by short-chain fatty acids: Implications for epithelial protection. *Biochem. J.* **2009**, *420*, 211–219. [[CrossRef](#)]
54. Bernet, M.F.; Brassart, D.; Neeser, J.R.; Servin, A.L. Adhesion of human bifidobacterial strains to cultured human intestinal epithelial cells and inhibition of enteropathogen-cell interactions. *Appl. Environ. Microbiol.* **1993**, *59*, 4121–4128.
55. Bernet, M.F.; Brassart, D.; Neeser, J.R.; Servin, A.L. *Lactobacillus acidophilus* LA 1 binds to cultured human intestinal cell lines and inhibits cell attachment and cell invasion by enterovirulent bacteria. *Gut* **1994**, *35*, 483–489. [[CrossRef](#)] [[PubMed](#)]
56. Munoz-Provencio, D.; Llopis, M.; Antolin, M.; de Torres, I.; Guarner, F.; Perez-Martinez, G.; Monedero, V. Adhesion properties of *Lactobacillus casei* strains to resected intestinal fragments and components of the extracellular matrix. *Arch. Microbiol.* **2009**, *191*, 153–161. [[CrossRef](#)] [[PubMed](#)]

57. Uroić, K.; Nikolić, M.; Kos, B.; Pavunc, A.L.; Beganović, J.; Lukić, J.; Jovčić, B.; Filipić, B.; Miljković, M.; Golić, N.; et al. Probiotic Properties of Lactic Acid Bacteria Isolated from Croatian Fresh Soft Cheese and Serbian White Pickled Cheese. *Food Technol. Biotechnol.* **2014**, *52*, 232–241.
58. Frece, J.; Kos, B.; Svetec, I.K.; Zgaga, Z.; Mrsa, V.; Susković, J. Importance of S-layer proteins in probiotic activity of *Lactobacillus acidophilus* M92. *J. Appl. Microbiol.* **2005**, *98*, 285–292. [[CrossRef](#)] [[PubMed](#)]
59. Beganović, J.; Frece, J.; Kos, B.; Pavunc, A.L.; Habjanič, K.; Susković, J. Functionality of the S-layer protein from the probiotic strain *Lactobacillus helveticus* M92. *Antonie van Leeuwenhoek* **2011**, *100*, 43–53. [[CrossRef](#)] [[PubMed](#)]
60. Mukai, T.; Kaneko, S.; Matsumoto, M.; Otori, H. Binding of *Bifidobacterium bifidum* and *Lactobacillus reuteri* to the carbohydrate moieties of intestinal glycolipids recognized by peanut agglutinin. *Int. J. Food Microbiol.* **2004**, *90*, 357–362. [[CrossRef](#)]
61. Tallon, R.; Arias, S.; Bressollier, P.; Urdaci, M.C. Strain- and matrix-dependent adhesion of *Lactobacillus plantarum* is mediated by proteinaceous bacterial compounds. *J. Appl. Microbiol.* **2007**, *102*, 442–451. [[CrossRef](#)] [[PubMed](#)]
62. Caballero-Franco, C.; Keller, K.; De Simone, C.; Chadee, K. The VSL#3 probiotic formula induces mucin gene expression and secretion in colonic epithelial cells. *Am. J. Physiol. Gastrointest. Liver Physiol.* **2007**, *292*, G315–G322. [[PubMed](#)]
63. Mack, D.R.; Michail, S.; Wei, S.; McDougall, L.; Hollingsworth, M.A. Probiotics inhibit enteropathogenic *E. coli* adherence in vitro by inducing intestinal mucin gene expression. *Am. J. Physiol.* **1999**, *276*, G941–G950.
64. Scheppach, W. Effects of short-chain fatty acids on gut morphology and function. *Gut* **1994**, *35*, S35–S38. [[CrossRef](#)] [[PubMed](#)]
65. Peng, L.; Li, Z.R.; Green, R.S.; Holzman, I.R.; Lin, J. Butyrate enhances the intestinal barrier by facilitating tight junction assembly via activation of AMP-activated protein kinase in Caco-2 cell monolayers. *J. Nutr.* **2009**, *139*, 1619–1625. [[CrossRef](#)] [[PubMed](#)]
66. Plöger, S.; Stumpff, F.; Penner, G.B.; Schulzke, J.D.; Gäbel, G.; Martens, H.; Shen, Z.; Günzel, D.; Aschenbach, J.R. Microbial butyrate and its role for barrier function in the gastrointestinal tract. *Ann. N. Y. Acad. Sci.* **2012**, *1258*, 52–59. [[CrossRef](#)] [[PubMed](#)]
67. Säemann, M.D.; Böhmig, G.A.; Osterreicher, C.H.; Burtscher, H.; Parolini, O.; Diakos, C.; Stöckl, J.; Hörl, W.H.; Zlabinger, G.J. Anti-inflammatory effects of sodium butyrate on human monocytes: Potent inhibition of IL-12 and up-regulation of IL-10 production. *FASEB J.* **2000**, *14*, 2380–2382. [[CrossRef](#)] [[PubMed](#)]
68. Segain, J.P.; Raingeard de la Blétière, D.; Bourreille, A.; Leray, V.; Gervois, N.; Rosales, C.; Ferrier, L.; Bonnet, C.; Blottière, H.M.; Galmiche, J.P. Butyrate inhibits inflammatory responses through NF kappa B inhibition: Implications for Crohn's disease. *Gut* **2000**, *47*, 397–403. [[CrossRef](#)] [[PubMed](#)]
69. Hamer, H.M.; Jonkers, D.M.; Bast, A.; Vanhoutvin, S.A.; Fischer, M.A.; Kodde, A.; Troost, F.J.; Venema, K.; Brummer, R.J. Butyrate modulates oxidative stress in the colonic mucosa of healthy humans. *Clin. Nutr.* **2009**, *28*, 88–93. [[CrossRef](#)] [[PubMed](#)]
70. Davies, K.J. Oxidative stress, antioxidant defenses, and damage removal, repair, and replacement systems. *IUBMB Life* **2000**, *50*, 279–289. [[CrossRef](#)] [[PubMed](#)]
71. Kullisaar, T.; Zilmer, M.; Mikelsaar, M.; Vihalemm, T.; Annuk, H.; Kairane, C.; Kilk, A. Two antioxidative lactobacilli strains as promising probiotics. *Int. J. Food Microbiol.* **2002**, *72*, 215–224. [[CrossRef](#)]
72. An, H.; Zhai, Z.; Yin, S.; Luo, Y.; Han, B.; Hao, Y. Coexpression of the superoxide dismutase and the catalase provides remarkable oxidative stress resistance in *Lactobacillus rhamnosus*. *J. Agric. Food Chem.* **2011**, *59*, 3851–3856. [[CrossRef](#)]
73. Sengul, N.; Isik, S.; Aslim, B.; Ucar, G.; Demirbag, A.E. The effect of exopolysaccharide-producing probiotic strains on gut oxidative damage in experimental colitis. *Dig. Dis. Sci.* **2011**, *56*, 707–714. [[CrossRef](#)]
74. Graves, J.A.; Metukuri, M.; Scott, D.; Rothermund, K.; Prochownik, E.V. Regulation of reactive oxygen species homeostasis by peroxiredoxins and c-Myc. *J. Biol. Chem.* **2009**, *284*, 6520–6529. [[CrossRef](#)] [[PubMed](#)]
75. Wu, R.Y.; Jeffrey, M.P.; Johnson-Henry, K.C.; Green-Johnson, J.M.; Sherman, P.M. Impact of prebiotics, probiotics, and gut derived metabolites on host immunity. *LymphoSign J.* **2017**, *4*, 1–24. [[CrossRef](#)]
76. Meijer, K.; de Vos, P.; Priebe, M.G. Butyrate and other short-chain fatty acids as modulators of immunity: What relevance for health? *Curr. Opin. Clin. Nutr. Metab. Care* **2010**, *13*, 715–721. [[CrossRef](#)] [[PubMed](#)]
77. Hemarajata, P.; Versalovic, J. Effects of probiotics on gut microbiota: Mechanisms of intestinal immunomodulation and neuromodulation. *Ther. Adv. Gastroenterol.* **2013**, *6*, 39–51. [[CrossRef](#)] [[PubMed](#)]

78. Nurmi, J.T.; Puolakkainen, P.A.; Rautonen, N.E. *Bifidobacterium Lactis* sp. 420 up-regulates cyclooxygenase (Cox)-1 and down-regulates Cox-2 gene expression in a Caco-2 cell culture model. *Nutr. Cancer* **2005**, *51*, 83–92. [[CrossRef](#)] [[PubMed](#)]
79. Marchetti, C.; Migliorati, G.; Moraca, R.; Riccardi, C.; Nicoletti, I.; Fabiani, R.; Mastrandrea, V.; Morozzi, G. Deoxycholic acid and SCFA-induced apoptosis in the human tumor cell-line HT-29 and possible mechanisms. *Cancer Lett.* **1997**, *114*, 97–99. [[CrossRef](#)]
80. Hague, A.; Elder, D.J.; Hicks, D.J.; Paraskeva, C. Apoptosis in colorectal tumour cells: Induction by the short-chain fatty acids butyrate, propionate and acetate and by the bile salt deoxycholate. *Int. J. Cancer* **1995**, *60*, 400–406. [[CrossRef](#)] [[PubMed](#)]
81. Morotomi, M.; Mutal, M. In vitro binding of potent mutagenic pyrolyzates to intestinal bacteria. *J. Natl. Cancer Inst.* **1986**, *77*, 195–201. [[PubMed](#)]
82. Zhang, X.B.; Ohta, Y. In vitro binding of mutagenic pyrolyzates to lactic acid bacterial cells in human gastric juice. *J. Dairy Sci.* **1991**, *74*, 752–757. [[CrossRef](#)]
83. Orrhage, K.; Sillerström, E.; Gustafsson, J.-Å.; Nord, C.; Rafter, J. Binding of mutagenic heterocyclic amines by intestinal and lactic acid bacteria. *Mutat. Res./Fund. Mol. Mech. Mutagen.* **1994**, *311*, 239–248. [[CrossRef](#)]
84. Fukushima, A.; Aizaki, Y.; Sakuma, K. Short-chain fatty acids increase the level of calbindin-D9k messenger RNA in Caco-2 cells. *J. Nutr. Sci. Vitaminol.* **2012**, *58*, 287–291. [[CrossRef](#)]
85. Davie, J.R. Inhibition of histone deacetylase activity by butyrate. *J. Nutr.* **2003**, *133*, 2485S–2493S. [[CrossRef](#)] [[PubMed](#)]
86. Aoyama, M.; Kotani, J.; Usami, M. Butyrate and propionate induced activated or non-activated neutrophil apoptosis via HDAC inhibitor activity but without activating GPR-41/GPR-43 pathways. *Nutrition* **2010**, *26*, 653–661. [[CrossRef](#)] [[PubMed](#)]
87. Brown, A.J.; Goldsworthy, S.M.; Barnes, A.A.; Eilert, M.M.; Tcheang, L.; Daniels, D.; Muir, A.I.; Wigglesworth, M.J.; Kinghorn, I.; Fraser, N.J.; et al. The Orphan G protein-coupled receptors GPR41 and GPR43 are activated by propionate and other short chain carboxylic acids. *J. Biol. Chem.* **2003**, *278*, 11312–11319. [[CrossRef](#)]
88. Karaki, S.; Mitsui, R.; Hayashi, H.; Kato, I.; Sugiyama, H.; Iwanaga, T.; Furness, J.B.; Kuwahara, A. Short-chain fatty acid receptor, GPR43, is expressed by enteroendocrine cells and mucosal mast cells in rat intestine. *Cell Tissue Res.* **2006**, *324*, 353–360. [[CrossRef](#)]
89. Bronner, F.; Pansu, D. Nutritional aspects of calcium absorption. *J. Nutr.* **1999**, *129*, 9–12. [[CrossRef](#)]
90. Palacios, C.; Martin, B.R.; McCabe, G.P.; McCabe, L.; Peacock, M.; Weaver, C.M. Dietary calcium requirements do not differ between Mexican-American boys and girls. *J. Nutr.* **2014**, *144*, 1167–1173. [[CrossRef](#)]
91. Wastney, M.E.; Martin, B.R.; Peacock, M.; Smith, D.; Jiang, X.Y.; Jackman, L.A.; Weaver, C.M. Changes in calcium kinetics in adolescent girls induced by high calcium intake. *J. Clin. Endocrinol. Metab.* **2000**, *85*, 4470–4475. [[CrossRef](#)]
92. Phang, J.M.; Berman, M.; Finerman, G.A.; Neer, R.M.; Rosenberg, L.E.; Hahn, T.J. Dietary perturbation of calcium metabolism in normal man: Compartmental analysis. *J. Clin. Invest.* **1969**, *48*, 67–77. [[CrossRef](#)] [[PubMed](#)]
93. Yan, J.; Herzog, J.W.; Tsang, K.; Brennan, C.A.; Bower, M.A.; Garrett, W.S.; Sartor, B.R.; Aliprantis, A.O.; Charles, J.F. Gut microbiota induce IGF-1 and promote bone formation and growth. *Proc. Natl. Acad. Sci. USA* **2016**, *113*, E7554–E7563. [[CrossRef](#)]
94. Yan, J.; Takakura, A.; Zandi-Nejad, K.; Charles, J.F. Mechanisms of gut microbiota-mediated bone remodeling. *Gut Microbes* **2018**, *9*, 84–92. [[CrossRef](#)] [[PubMed](#)]
95. Wang, Y.; Nishida, S.; Elalieh, H.Z.; Long, R.K.; Halloran, B.P.; Bikle, D.D. Role of IGF-I signaling in regulating osteoclastogenesis. *J. Bone Miner. Res.* **2006**, *21*, 1350–1358. [[CrossRef](#)] [[PubMed](#)]
96. Wang, Y.; Nishida, S.; Boudignon, B.M.; Burghardt, A.; Elalieh, H.Z.; Hamilton, M.M.; Majumdar, S.; Halloran, B.P.; Clemens, T.L.; Bikle, D.D. IGF-I receptor is required for the anabolic actions of parathyroid hormone on bone. *J. Bone Miner. Res.* **2007**, *22*, 1329–1337. [[CrossRef](#)] [[PubMed](#)]
97. Fulzele, K.; DiGirolamo, D.J.; Liu, Z.; Xu, J.; Messina, J.L.; Clemens, T.L. Disruption of the insulin-like growth factor type 1 receptor in osteoblasts enhances insulin signaling and action. *J. Biol. Chem.* **2007**, *282*, 25649–25658. [[CrossRef](#)] [[PubMed](#)]

98. Yakar, S.; Rosen, C.J.; Beamer, W.G.; Ackert-Bicknell, C.L.; Wu, Y.; Liu, J.L.; Ooi, G.T.; Setser, J.; Frystyk, J.; Boisclair, Y.R.; et al. Circulating levels of IGF-1 directly regulate bone growth and density. *J. Clin. Investig.* **2002**, *110*, 771–781. [[CrossRef](#)] [[PubMed](#)]
99. Pandey, K.R.; Naik, S.R.; Vakil, B.V. Probiotics, prebiotics and synbiotics—a review. *J. Food Sci. Technol.* **2015**, *52*, 7577–7587. [[CrossRef](#)] [[PubMed](#)]
100. McCabe, L.R.; Irwin, R.; Schaefer, L.; Britton, R.A. Probiotic use decreases intestinal inflammation and increases bone density in healthy male but not female mice. *J. Cell. Physiol.* **2013**, *228*, 1793–1798. [[CrossRef](#)] [[PubMed](#)]
101. Zhang, J.; Motyl, K.J.; Irwin, R.; MacDougald, O.A.; Britton, R.A.; McCabe, L.R. Loss of Bone and Wnt10b Expression in Male Type 1 Diabetic Mice Is Blocked by the Probiotic *Lactobacillus reuteri*. *Endocrinology* **2015**, *156*, 3169–3182. [[CrossRef](#)]
102. Britton, R.A.; Irwin, R.; Quach, D.; Schaefer, L.; Zhang, J.; Lee, T.; Parameswaran, N.; McCabe, L.R. Probiotic *L. reuteri* treatment prevents bone loss in a menopausal ovariectomized mouse model. *J. Cell. Physiol.* **2014**, *229*, 1822–1830. [[CrossRef](#)]
103. Ohlsson, C.; Engdahl, C.; Fåk, F.; Andersson, A.; Windahl, S.H.; Farman, H.H.; Movérare-Skrtic, S.; Islander, U.; Sjögren, K. Probiotics protect mice from ovariectomy-induced cortical bone loss. *PLoS ONE* **2014**, *9*, e92368. [[CrossRef](#)]
104. Decroos, K.; Vanhemmens, S.; Cattoir, S.; Boon, N.; Verstraete, W. Isolation and characterization of an equol-producing mixed microbial culture from a human faecal sample and its activity under gastrointestinal conditions. *Arch. Microbiol.* **2005**, *183*, 45–55. [[CrossRef](#)]
105. Breinholt, V.; Hossaini, A.; Svendsen, G.W.; Brouwer, C.; Nielsen, E. Estrogenic activity of flavonoids in mice. The importance of estrogen receptor distribution, metabolism and bioavailability. *Food Chem. Toxicol.* **2000**, *38*, 555–564. [[CrossRef](#)]
106. Nishide, Y.; Tadaishi, M.; Kobori, M.; Tosen, Y.; Kato, M.; Inada, M.; Miyaura, C.; Ishimi, Y. Possible role of S-equol on bone loss via amelioration of inflammatory indices in ovariectomized mice. *J. Clin. Biochem. Nutr.* **2013**, *53*, 41–48. [[CrossRef](#)]
107. Chonan, O.; Matsumoto, K.; Watanuki, M. Effect of galactooligosaccharides on calcium absorption and preventing bone loss in ovariectomized rats. *Biosci. Biotechnol. Biochem.* **1995**, *59*, 236–239. [[CrossRef](#)]
108. Zheng, W.; Hou, Y.; Su, Y.; Yao, W. Lactulose promotes equol production and changes the microbial community during in vitro fermentation of daidzein by fecal inocula of sows. *Anaerobe* **2014**, *25*, 47–52. [[CrossRef](#)] [[PubMed](#)]
109. Zheng, W.; Hou, Y.; Yao, W. Lactulose Increases Equol Production and Improves Liver Antioxidant Status in Barrows Treated with Daidzein. *PLoS ONE* **2014**, *9*, e93163. [[CrossRef](#)] [[PubMed](#)]
110. Pallauf, J.; Rimbach, G. Nutritional significance of phytic acid and phytase. *Arch. Tierernähr.* **1997**, *50*, 301–319. [[CrossRef](#)]
111. Mullaney, E.J.; Daly, C.B.; Kim, T.; Porres, J.M.; Lei, X.G.; Sethumadhavan, K.; Ullah, A.H. Site-directed mutagenesis of *Aspergillus niger* NRRL 3135 phytase at residue 300 to enhance catalysis at pH 4.0. *Biochem. Biophys. Res. Commun.* **2002**, *297*, 1016–1020. [[CrossRef](#)]
112. Raghavendra, P.; Halami, P.M. Screening, selection and characterization of phytic acid degrading lactic acid bacteria from chicken intestine. *Int. J. Food Microbiol.* **2009**, *133*, 129–134. [[CrossRef](#)]
113. Famularo, G.; De Simone, C.; Pandey, V.; Sahu, A.R.; Minisola, G. Probiotic lactobacilli: An innovative tool to correct the malabsorption syndrome of vegetarians? *Med. Hypotheses* **2005**, *65*, 1132–1135. [[CrossRef](#)]
114. Askelson, T.E.; Campasino, A.; Lee, J.T.; Duong, T. Evaluation of Phytate-Degrading *Lactobacillus* Culture Administration to Broiler Chickens. *Appl. Environ. Microbiol.* **2014**, *80*, 943–950. [[CrossRef](#)]
115. Anandharaj, M.; Sivasankari, B.; Rani, R.P. Effects of Probiotics, Prebiotics, and Synbiotics on Hypercholesterolemia: A Review. *Chin. J. Biol.* **2014**, *2014*, 1–7. [[CrossRef](#)]
116. WHO. *Diet, Nutrition and Prevention of Chronic Diseases*; Report of a Joint WHO/FAO Expert Consultation; WHO: Geneva, Switzerland, 2003.
117. Shattat, G.F. A Review Article on Hyperlipidemia: Types, Treatments and New Drug Targets. *Biomed. Pharmacol. J.* **2014**, *7*, 399–409. [[CrossRef](#)]
118. Nestruck, A.C.; Davignon, J. Risks for hyperlipidemia. *Cardiol. Clin.* **1986**, *4*, 47–56. [[CrossRef](#)]
119. Clayton, D.; Woo, V.; Yale, J.F. Hypoglycemia. *Can. J. Diabetes* **2013**, *37*, S69–S71. [[CrossRef](#)] [[PubMed](#)]

120. Vamanu, E.; Pelinescu, D.; Sarbu, I. Comparative Fingerprinting of the Human Microbiota in Diabetes and Cardiovascular Disease. *J. Med. Food* **2016**, *19*, 1188–1195. [[CrossRef](#)] [[PubMed](#)]
121. Tang, W.H.; Kitai, T.; Hazen, S.L. Gut Microbiota in Cardiovascular Health and Disease. *Circ. Res.* **2017**, *120*, 1183–1196. [[CrossRef](#)]
122. Ghazalpour, A.; Cespedes, I.; Bennett, B.J.; Allayee, H. Expanding role of gut microbiota in lipid metabolism. *Curr. Opin. Lipidol.* **2016**, *27*, 141–147. [[CrossRef](#)]
123. Vogt, J.A.; Ishii-Schrade, K.B.; Pencharz, P.B.; Jones, P.J.; Wolever, T.M. L-rhamnose and lactulose decrease serum triacylglycerols and their rates of synthesis, but do not affect serum cholesterol concentrations in men. *J. Nutr.* **2006**, *136*, 2160–2166. [[CrossRef](#)]
124. Vulevic, J.; Juric, A.; Tzortzis, G.; Gibson, G.R. A mixture of trans-galactooligosaccharides reduces markers of metabolic syndrome and modulates the fecal microbiota and immune function of overweight adults. *J. Nutr.* **2013**, *143*, 324–331. [[CrossRef](#)]
125. Taylor, G.R.; Williams, C.M. Effects of probiotics and prebiotics on blood lipids. *Br. J. Nutr.* **1998**, *80*, S225–S230.
126. Pereira, D.I.; Gibson, G.R. Effects of Consumption of Probiotics and Prebiotics on Serum Lipid Levels in Humans. *Crit. Rev. Biochem. Mol. Biol.* **2002**, *37*, 259–281. [[CrossRef](#)] [[PubMed](#)]
127. Midtvedt, T. Microbial bile acid transformation. *Am. J. Clin. Nutr.* **1974**, *27*, 1341–1347. [[CrossRef](#)]
128. Gérard, P. Metabolism of Cholesterol and Bile Acids by the Gut Microbiota. *Pathogens* **2014**, *3*, 14–24. [[CrossRef](#)] [[PubMed](#)]
129. Kumar, M.; Nagpal, R.; Kumar, R.; Hemalatha, R.; Verma, V.; Kumar, A.; Chakraborty, C.; Singh, B.; Marotta, F.; Jain, S.; et al. Cholesterol-lowering probiotics as potential biotherapeutics for metabolic diseases. *Exp. Diabetes Res.* **2012**, *2012*, 902917. [[CrossRef](#)] [[PubMed](#)]
130. Kasubuchi, M.; Hasegawa, S.; Hiramatsu, T.; Ichimura, A.; Kimura, I. Dietary gut microbial metabolites, short-chain fatty acids, and host metabolic regulation. *Nutrients* **2015**, *7*, 2839–2849. [[CrossRef](#)] [[PubMed](#)]
131. Trautwein, E.A.; Rieckhoff, D.; Erbersdobler, H.F. Dietary inulin lowers plasma cholesterol and triacylglycerol and alters biliary bile acid profile in hamsters. *J. Nutr.* **1998**, *128*, 1937–1943. [[CrossRef](#)] [[PubMed](#)]
132. Kumar, M.; Nagpal, R.; Kumar, R.; Hemalatha, R.; Verma, V.; Kumar, A.; Chakraborty, C.; Singh, B.; Marotta, F.; Jain, S.; et al. Acetate and butyrate are the major substrates for de novo lipogenesis in rat colonic epithelial cells. *Exp. Diabetes Res.* **2012**, *2012*, 902917.
133. Nishina, P.M.; Freedland, R.A. Effects of propionate on lipid biosynthesis in isolated rat hepatocytes. *J. Nutr.* **1990**, *120*, 668–673. [[CrossRef](#)] [[PubMed](#)]
134. Hong, Y.H.; Nishimura, Y.; Hishikawa, D.; Tsuzuki, H.; Miyahara, H.; Gotoh, C.; Choi, K.C.; Feng, D.D.; Chen, C.; Lee, H.G.; et al. Acetate and propionate short chain fatty acids stimulate adipogenesis via GPCR43. *Endocrinology* **2005**, *146*, 5092–5099. [[CrossRef](#)]
135. Donnelly, K.L.; Smith, C.I.; Schwarzenberg, S.J.; Jessurun, J.; Boldt, M.D.; Parks, E.J. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. *J. Clin. Investig.* **2005**, *115*, 1343–1351. [[CrossRef](#)]
136. Noh, D.O.; Gilliland, S.E. Influence of bile on cellular integrity and beta-galactosidase activity of *Lactobacillus acidophilus*. *J. Dairy Sci.* **1993**, *76*, 1253–1259. [[CrossRef](#)]
137. Al-Lahham, S.; Roelofsen, H.; Rezaee, F.; Weening, D.; Hoek, A.; Vonk, R.; Venema, K. Propionic acid affects immune status and metabolism in adipose tissue from overweight subjects. *Eur. J. Clin. Invest.* **2012**, *42*, 357–364. [[CrossRef](#)] [[PubMed](#)]
138. Alex, S.; Lange, K.; Amolo, T.; Grinstead, J.S.; Haakonsson, A.K.; Szalowska, E.; Koppen, A.; Mudde, K.; Haenen, D.; Al-Lahham, S.; et al. Short-Chain Fatty Acids Stimulate Angiopoietin-Like 4 Synthesis in Human Colon Adenocarcinoma Cells by Activating Peroxisome Proliferator-Activated Receptor γ . *Mol. Cell. Biol.* **2013**, *33*, 1303–1316. [[CrossRef](#)] [[PubMed](#)]
139. Yoshida, K.; Shimizugawa, T.; Ono, M.; Furukawa, H. Angiopoietin-like protein 4 is a potent hyperlipidemia-inducing factor in mice and inhibitor of lipoprotein lipase. *J. Lipid Res.* **2002**, *43*, 1770–1772. [[CrossRef](#)] [[PubMed](#)]
140. Bäckhed, F.; Ding, H.; Wang, T.; Hooper, L.V.; Koh, G.Y.; Nagy, A.; Semenkovich, C.F.; Gordon, J.I. The gut microbiota as an environmental factor that regulates fat storage. *Proc. Natl. Acad. Sci. USA* **2004**, *101*, 15718–15723. [[CrossRef](#)] [[PubMed](#)]

141. Aronsson, L.; Huang, Y.; Parini, P.; Korach-André, M.; Håkansson, J.; Gustafsson, J.Å.; Pettersson, S.; Arulampalam, V.; Rafter, J. Decreased Fat Storage by *Lactobacillus Paracasei* Is Associated with Increased Levels of Angiopoietin-Like 4 Protein (ANGPTL4). *PLoS ONE* **2010**, *5*, e13087. [[CrossRef](#)] [[PubMed](#)]
142. Bäckhed, F.; Manchester, J.K.; Semenkovich, C.F.; Gordon, J.I. Mechanisms underlying the resistance to diet-induced obesity in germ-free mice. *Proc. Natl. Acad. Sci. USA* **2007**, *104*, 979–984. [[CrossRef](#)]
143. Li, X.; Chen, H.; Guan, Y.; Li, X.; Lei, L.; Liu, J.; Yin, L.; Liu, G.; Wang, Z. Acetic acid activates the AMP-activated protein kinase signaling pathway to regulate lipid metabolism in bovine hepatocytes. *PLoS ONE* **2013**, *8*, e67880. [[CrossRef](#)]
144. Sakakibara, S.; Yamauchi, T.; Oshima, Y.; Tsukamoto, Y.; Kadowaki, T. Acetic acid activates hepatic AMPK and reduces hyperglycemia in diabetic KK-A(y) mice. *Biochem. Biophys. Res. Commun.* **2006**, *344*, 597–604. [[CrossRef](#)]
145. Donohoe, D.R.; Garge, N.; Zhang, X.; Sun, W.; O’Connell, T.M.; Bunger, M.K.; Bultman, S.J. The microbiome and butyrate regulate energy metabolism and autophagy in the mammalian colon. *Cell MeTab.* **2011**, *13*, 517–526. [[CrossRef](#)]
146. Gao, Z.; Yin, J.; Zhang, J.; Ward, R.E.; Martin, R.J.; Lefevre, M.; Cefalu, W.T.; Ye, J. Butyrate improves insulin sensitivity and increases energy expenditure in mice. *Diabetes* **2009**, *58*, 1509–1517. [[CrossRef](#)] [[PubMed](#)]
147. Thomas, C.; Gioiello, A.; Noriega, L.; Strehle, A.; Oury, J.; Rizzo, G.; Macchiarulo, A.; Yamamoto, H.; Matak, C.; Pruzanski, M.; et al. TGR5-mediated bile acid sensing controls glucose homeostasis. *Cell MeTab.* **2009**, *10*, 167–177. [[CrossRef](#)] [[PubMed](#)]
148. Trabelsi, M.S.; Daoudi, M.; Prawitt, J.; Ducastel, S.; Touche, V.; Sayin, S.I.; Perino, A.; Brighton, C.A.; Sebt, Y.; Kluza, J.; et al. Farnesoid X receptor inhibits glucagon-like peptide-1 production by enteroendocrine L cells. *Nat. Commun.* **2015**, *6*, 7629. [[CrossRef](#)]
149. Kimura, I.; Ozawa, K.; Inoue, D.; Imamura, T.; Kimura, K.; Maeda, T.; Terasawa, K.; Kashihara, D.; Hirano, K.; Tani, T.; et al. The gut microbiota suppresses insulin-mediated fat accumulation via the short-chain fatty acid receptor GPR43. *Nat. Commun.* **2013**, *4*, 1829. [[CrossRef](#)] [[PubMed](#)]
150. den Besten, G.; Bleeker, A.; Gerding, A.; van Eunen, K.; Havinga, R.; van Dijk, T.H.; Oosterveer, M.H.; Jonker, J.W.; Groen, A.K.; Reijngoud, D.J.; et al. Short-chain fatty acids protect against high-fat diet-induced obesity via a PPAR γ -dependent switch from lipogenesis to fat oxidation. *Diabetes* **2015**, *64*, 2398–2408. [[CrossRef](#)] [[PubMed](#)]
151. Xiong, Y.; Miyamoto, N.; Shibata, K.; Valasek, M.A.; Motoike, T.; Kedzierski, R.M.; Yanagisawa, M. Short-chain fatty acids stimulate leptin production in adipocytes through the G protein-coupled receptor GPR41. *Proc. Natl. Acad. Sci. USA* **2004**, *101*, 1045–1050. [[CrossRef](#)] [[PubMed](#)]
152. Minokoshi, Y.; Kim, Y.B.; Peroni, O.D.; Fryer, L.G.; Müller, C.; Carling, D.; Kahn, B.B. Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase. *Nature* **2002**, *415*, 339–343. [[CrossRef](#)] [[PubMed](#)]
153. Utzschneider, K.M.; Kratz, M.; Damman, C.J.; Hullar, M. Mechanisms Linking the Gut Microbiome and Glucose Metabolism. *J. Clin. Endocrinol. MeTab.* **2016**, *101*, 1445–1454. [[CrossRef](#)] [[PubMed](#)]
154. Razin, S. Cholesterol incorporation into bacterial membranes. *J. Bacteriol.* **1975**, *124*, 570–572.
155. Dambekodi, P.C.; Gilliland, S.E. Incorporation of cholesterol into the cellular membrane of *Bifidobacterium longum*. *J. Dairy Sci.* **1998**, *81*, 1818–1824. [[CrossRef](#)]
156. Pato, U.; Hosono, A. Bile tolerance, taurocholate deconjugation, and binding of cholesterol by *Lactobacillus gasseri* strains. *J. Dairy Sci.* **1999**, *82*, 243–248.
157. Taranto, M.P.; Sesma, F.; de Ruiz Holgado, A.P.; de Valdez, G.F. Bile salts hydrolase plays a key role on cholesterol removal by *Lactobacillus reuteri*. *Biotechnol. Lett.* **1997**, *19*, 845–847. [[CrossRef](#)]
158. Lye, H.S.; Rahmat-Ali, G.R.; Liong, M.T. Mechanisms of Cholesterol Removal by Lactobacilli Under Conditions That Mimic the Human Gastrointestinal Tract. *Int. Dairy J.* **2010**, *20*, 169–175. [[CrossRef](#)]
159. Lye, H.S.; Rusul, G.; Liong, M.T. Removal of Cholesterol by Lactobacilli via Incorporation of and Conversion to Coprostanol. *J. Dairy Sci.* **2010**, *93*, 1383–1392. [[CrossRef](#)] [[PubMed](#)]
160. Kimoto, H.; Ohmomo, S.; Okamoto, T. Cholesterol removal from media by lactococci. *J. Dairy Sci.* **2002**, *85*, 3182–3188. [[CrossRef](#)]
161. Lin, M.Y.; Chen, T.W. Reduction of Cholesterol by *Lactobacillus acidophilus* in Culture Broth. *J. Food Drug Anal.* **2000**, *8*, 97–102.

162. Xiao, J.Z.; Kondo, S.; Takahashi, N.; Miyaji, K.; Oshida, K.; Hiramatsu, A.; Iwatsuki, K.; Kokubo, S.; Hosono, A. Effects of milk products fermented by *Bifidobacterium longum* on blood lipids in rats and healthy adult male volunteers. *J. Dairy Sci.* **2003**, *86*, 2452–2461. [[CrossRef](#)]
163. Allayee, H.; Hazen, S.L. Contribution of Gut Bacteria to Lipid Levels: Another Metabolic Role for Microbes? *Circ. Res.* **2015**, *117*, 750–754. [[CrossRef](#)]
164. Ridlon, J.M.; Harris, S.C.; Bhowmik, S.; Kang, D.J.; Hylemon, P.B. Consequences of bile salt biotransformations by intestinal bacteria. *Gut Microbes* **2016**, *7*, 22–39. [[CrossRef](#)]
165. Begley, M.; Hill, C.; Gahan, C.G. Bile salt hydrolase activity in probiotics. *Appl. Environ. Microbiol.* **2006**, *72*, 1729–1738. [[CrossRef](#)]
166. Ridlon, J.M.; Kang, D.J.; Hylemon, P.B. Bile salt biotransformations by human intestinal bacteria. *J. Lipid Res.* **2006**, *47*, 241–259. [[CrossRef](#)] [[PubMed](#)]
167. Heuman, D.M. Quantitative estimation of the hydrophilic-hydrophobic balance of mixed bile salt solutions. *J. Lipid Res.* **1989**, *30*, 719–730.
168. Lichtenstein, A.H. Intestinal Cholesterol Metabolism. *Ann. Med.* **1990**, *22*, 49–52. [[CrossRef](#)]
169. Chiang, Y.R.; Ismail, W.; Heintz, D.; Schaeffer, C.; Van Dorsselaer, A.; Fuchs, G. Study of anoxic and oxic cholesterol metabolism by *Sterolibacterium denitrificans*. *J. Bacteriol.* **2008**, *190*, 905–914. [[CrossRef](#)] [[PubMed](#)]
170. Macdonald, I.A.; Bokkenheuser, V.D.; Winter, J.; McLernon, A.M.; Mosbach, E.H. Degradation of steroids in the human gut. *J. Lipid Res.* **1983**, *24*, 675–700. [[PubMed](#)]
171. Papatheodorou, K.; Papanas, N.; Banach, M.; Papazoglou, D.; Edmonds, M. Complications of Diabetes 2016. *J. Diabetes Res.* **2016**, *2016*, 6989453. [[CrossRef](#)] [[PubMed](#)]
172. Stolar, M. Glycemic Control and Complications in Type 2 Diabetes Mellitus. *Am. J. Med.* **2010**, *123*, S3–S11. [[CrossRef](#)]
173. Röder, P.V.; Wu, B.; Liu, Y.; Han, W. Pancreatic regulation of glucose homeostasis. *Exp. Mol. Med.* **2016**, *48*, e219. [[CrossRef](#)]
174. Kahn, S.E.; Prigeon, R.L.; McCulloch, D.K.; Boyko, E.J.; Bergman, R.N.; Schwartz, M.W.; Neifing, J.L.; Ward, W.K.; Beard, J.C.; Palmer, J.P.; et al. Quantification of the relationship between insulin sensitivity and beta-cell function in human subjects. Evidence for a hyperbolic function. *Diabetes* **1993**, *42*, 1663–1672. [[CrossRef](#)]
175. Fatati, G.; Mirri, E.; Coaccioli, S. Effects of visceral fat accumulation in obesity and type 2 diabetes. *Med. J. Nutr. MeTab.* **2009**, *2*, 111–118. [[CrossRef](#)]
176. Iozzo, P. Viewpoints on the way to the consensus session: Where does insulin resistance start? The adipose tissue. *Diabetes Care* **2009**, *32*, S168–S173. [[CrossRef](#)]
177. Yoo, J.Y.; Kim, S.S. Probiotics and Prebiotics: Present Status and Future Perspectives on Metabolic Disorders. *Nutrients* **2016**, *8*, 173. [[CrossRef](#)]
178. Pickup, J.C.; Crook, M.A. Is type II diabetes mellitus a disease of the innate immune system? *Diabetologia* **1998**, *41*, 1241–1248. [[CrossRef](#)]
179. Grimble, R.F. Inflammatory status and insulin resistance. *Curr. Opin. Clin. Nutr. Metab. Care* **2002**, *5*, 551–559. [[CrossRef](#)] [[PubMed](#)]
180. Morrison, D.J.; Preston, T. Formation of short chain fatty acids by the gut microbiota and their impact on human metabolism. *Gut Microbes* **2016**, *7*, 189–200. [[CrossRef](#)] [[PubMed](#)]
181. Janssen, A.W.; Kersten, S. The role of the gut microbiota in metabolic health. *FASEB J.* **2015**, *29*, 3111–3123. [[CrossRef](#)] [[PubMed](#)]
182. He, C.; Shan, Y.; Song, W. Targeting gut microbiota as a possible therapy for diabetes. *Nutr. Res.* **2015**, *35*, 361–367. [[CrossRef](#)] [[PubMed](#)]
183. Mooradian, A.D.; Morley, J.E.; Levine, A.S.; Prigge, W.F.; Gebhard, R.L. Abnormal intestinal permeability to sugars in diabetes mellitus. *Diabetologia* **1986**, *29*, 221–224. [[CrossRef](#)] [[PubMed](#)]
184. Bianchi, G.; Ronchi, M.; Marchesini, G. Effect of lactulose on carbohydrate metabolism and diabetes mellitus. *Scand. J. Gastroenterol. Suppl.* **1997**, *222*, 62–64. [[CrossRef](#)] [[PubMed](#)]
185. Kim, Y.A.; Keogh, J.B.; Clifton, P.M. Probiotics, prebiotics, synbiotics and insulin sensitivity. *Nutr. Res. Rev.* **2018**, *31*, 35–51. [[CrossRef](#)]
186. Gomes, A.C.; Bueno, A.A.; de Souza, R.G.; Mota, J.F. Gut microbiota, probiotics and diabetes. *Nutr. J.* **2014**, *13*, 60. [[CrossRef](#)] [[PubMed](#)]

187. Musso, G.; Gambino, R.; Cassader, M. Obesity, Diabetes, and Gut Microbiota. *Diabetes Care* **2010**, *33*, 2277–2284. [[CrossRef](#)] [[PubMed](#)]
188. Sáez-Lara, M.J.; Robles-Sanchez, C.; Ruiz-Ojeda, F.J.; Plaza-Diaz, J.; Gil, A. Effects of Probiotics and Synbiotics on Obesity, Insulin Resistance Syndrome, type 2 Diabetes and Non-Alcoholic Fatty Liver Disease: A Review of Human Clinical Trials. *Int. J. Mol. Sci.* **2016**, *17*, 928. [[CrossRef](#)] [[PubMed](#)]
189. Kellow, N.J.; Coughlan, M.T.; Savige, G.S.; Reid, C.M. Effect of dietary prebiotic supplementation on advanced glycation, insulin resistance and inflammatory biomarkers in adults with pre-diabetes: A study protocol for a double-blind placebo-controlled randomised crossover clinical trial. *BMC Endocr. Disord.* **2014**, *14*, 55. [[CrossRef](#)] [[PubMed](#)]
190. Batterham, R.L.; Cowley, M.A.; Small, C.J.; Herzog, H.; Cohen, M.A.; Dakin, C.L.; Wren, A.M.; Brynes, A.E.; Low, M.J.; Ghatei, M.A.; et al. Gut hormone PYY(3-36) physiologically inhibits food intake. *Nature* **2002**, *418*, 650–654. [[CrossRef](#)] [[PubMed](#)]
191. van den Hoek, A.M.; Heijboer, A.C.; Corssmit, E.P.; Voshol, P.J.; Romijn, J.A.; Havekes, L.M.; Pijl, H. PYY3-36 reinforces insulin action on glucose disposal in mice fed a high-fat diet. *Diabetes* **2004**, *53*, 1949–1952. [[CrossRef](#)]
192. Yamashita, H.; Fujisawa, K.; Ito, E.; Idei, S.; Kawaguchi, N.; Kimoto, M.; Hiemori, M.; Tsuji, H. Improvement of obesity and glucose tolerance by acetate in Type 2 diabetic Otsuka Long-Evans Tokushima Fatty (OLETF) rats. *Biosci. Biotechnol. Biochem.* **2007**, *71*, 1236–1243. [[CrossRef](#)] [[PubMed](#)]
193. Simon, M.C.; Strassburger, K.; Nowotny, B.; Kolb, H.; Nowotny, P.; Burkart, V.; Zivehe, F.; Hwang, J.H.; Stehle, P.; Pacini, G.; et al. Intake of *Lactobacillus reuteri* improves incretin and insulin secretion in glucose-tolerant humans: A proof of concept. *Diabetes Care* **2015**, *38*, 1827–1834. [[CrossRef](#)] [[PubMed](#)]
194. Yi, H.S.; Jeong, W.I. Interaction of hepatic stellate cells with diverse types of immune cells: Foe or friend? *J. Gastroenterol. Hepatol.* **2013**, *1*, 99–104. [[CrossRef](#)]
195. Montoliu, C.; Piedrafita, B.; Serra, M.A.; del Olmo, J.A.; Urios, A.; Rodrigo, J.M.; Felipo, V. IL-6 and IL-18 in blood may discriminate cirrhotic patients with and without minimal hepatic encephalopathy. *J. Clin. Gastroenterol.* **2009**, *43*, 272–279. [[CrossRef](#)]
196. De Vadder, F.; Kovatcheva-Datchary, P.; Goncalves, D.; Vinera, J.; Zitoun, C.; Duchamp, A.; Bäckhed, F.; Mithieux, G. Microbiota-generated metabolites promote metabolic benefits via gut-brain neural circuits. *Cell* **2014**, *156*, 84–96. [[CrossRef](#)]
197. Soty, M.; Penhoat, A.; Amigo-Correig, M.; Vinera, J.; Sardella, A.; Vullin-Bouilloux, F.; Zitoun, C.; Houberton, I.; Mithieux, G. A gut-brain neural circuit controlled by intestinal gluconeogenesis is crucial in metabolic health. *Mol. MeTab.* **2014**, *4*, 106–117. [[CrossRef](#)]
198. Xu, A.; Lam, M.C.; Chan, K.W.; Wang, Y.; Zhang, J.; Hoo, R.L.; Xu, J.Y.; Chen, B.; Chow, W.S.; Tso, A.W.; et al. Angiotensin-like protein 4 decreases blood glucose and improves glucose tolerance but induces hyperlipidemia and hepatic steatosis in mice. *Proc. Natl. Acad. Sci. USA* **2005**, *102*, 6086–6091. [[CrossRef](#)] [[PubMed](#)]
199. Ferré, P. The biology of peroxisome proliferator activated receptors relationship with lipid metabolism and insulin sensitivity. *Diabetes* **2004**, *53*, S43–S50. [[CrossRef](#)] [[PubMed](#)]
200. Bouskila, M.; Pajvani, U.B.; Scherer, P.E. Adiponectin: A relevant player in PPAR γ -agonist-mediated improvements in hepatic insulin sensitivity? *Int. J. Obes.* **2005**, *29*, S17–S23. [[CrossRef](#)] [[PubMed](#)]
201. Rutter, G.A.; Da Silva Xavier, G.; Leclerc, I. Roles of 5'-AMP-activated protein kinase (AMPK) in mammalian glucose homeostasis. *Biochem. J.* **2003**, *375*, 1–16. [[CrossRef](#)]
202. Al-Salami, H.; Butt, G.; Tucker, I.; Skrbic, R.; Golocorbin-Kon, S.; Mikov, M. Probiotic Pre-treatment Reduces Gliclazide Permeation (ex vivo) in Healthy Rats but Increases It in Diabetic Rats to the Level Seen in Untreated Healthy Rats. *Arch. Drug Inf.* **2008**, *1*, 35–41. [[CrossRef](#)]
203. Yamano, T.; Tanida, M.; Nijima, A.; Maeda, K.; Okumura, N.; Fukushima, Y.; Nagai, K. Effects of the probiotic strain *Lactobacillus johnsonii* strain La1 on autonomic nerves and blood glucose in rats. *Life Sci.* **2006**, *79*, 1963–1967. [[CrossRef](#)]
204. Dentin, R.; Pégorier, J.P.; Benhamed, F.; Fougelle, F.; Ferré, P.; Fauveau, V.; Magnuson, M.A.; Girard, J.; Postic, C. Hepatic glucokinase is required for the synergistic action of ChREBP and SREBP-1c on glycolytic and lipogenic gene expression. *J. Biol. Chem.* **2004**, *279*, 20314–20326. [[CrossRef](#)]
205. Kuipers, F.; Bloks, V.W.; Groen, A.K. Beyond intestinal soap–bile acids in metabolic control. *Nat. Rev. Endocrinol.* **2014**, *10*, 488–498. [[CrossRef](#)]

206. Schaap, F.G. Role of fibroblast growth factor 19 in the control of glucose homeostasis. *Curr. Opin. Clin. Nutr. Metab. Care* **2012**, *15*, 386–391. [[CrossRef](#)] [[PubMed](#)]
207. Renga, B.; Mencarelli, A.; Vavassori, P.; Brancaleone, V.; Fiorucci, S. The bile acid sensor FXR regulates insulin transcription and secretion. *Biochim. Biophys. Acta* **2010**, *1802*, 363–372. [[CrossRef](#)]
208. Mudaliar, S.; Henry, R.R.; Sanyal, A.J.; Morrow, L.; Marschall, H.U.; Kipnes, M.; Adorini, L.; Sciacca, C.I.; Clopton, P.; Castleoe, E.; et al. Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. *Gastroenterology* **2013**, *145*, 574–582. [[CrossRef](#)] [[PubMed](#)]
209. Ma, X.; Hua, J.; Li, Z. Probiotics Improve High Fat Diet-induced Hepatic Steatosis and Insulin Resistance by Increasing Hepatic NKT cells. *J. Hepatol.* **2008**, *49*, 821–830. [[CrossRef](#)]
210. Hotamisligil, G.S.; Shargill, N.S.; Spiegelman, B.M. Adipose expression of tumor necrosis factor- α : Direct role in obesity-linked insulin resistance. *Science* **1993**, *259*, 87–91. [[CrossRef](#)] [[PubMed](#)]
211. Hotamisligil, G.S.; Spiegelman, B.M. Tumor necrosis factor α : A key component of the obesity-diabetes link. *Diabetes* **1994**, *43*, 1271–1278. [[CrossRef](#)]
212. Cai, D.; Yuan, M.; Frantz, D.F.; Melendez, P.A.; Hansen, L.; Lee, J.; Shoelson, S.E. Local and systemic insulin resistance resulting from hepatic activation of IKK- β and NF- κ B. *Nat. Med.* **2005**, *11*, 183–190. [[CrossRef](#)]
213. Vinolo, M.A.; Rodrigues, H.G.; Hatanaka, E.; Sato, F.T.; Sampaio, S.C.; Curi, R. Suppressive effect of short-chain fatty acids on production of proinflammatory mediators by neutrophils. *J. Nutr. Biochem.* **2011**, *22*, 849–855. [[CrossRef](#)]
214. Luo, M.; Guo, J.Y.; Cao, W.K. Inflammation: A novel target of current therapies for hepatic encephalopathy in liver cirrhosis. *World J. Gastroenterol.* **2015**, *21*, 11815–11824. [[CrossRef](#)]
215. Park, J.S.; Lee, E.J.; Lee, J.C.; Kim, W.K.; Kim, H.S. Anti-inflammatory effects of short chain fatty acids in IFN- γ -stimulated RAW 264.7 murine macrophage cells: Involvement of NF- κ B and ERK signaling pathways. *Int. Immunopharmacol.* **2007**, *7*, 70–77. [[CrossRef](#)]
216. Usami, M.; Kishimoto, K.; Ohata, A.; Miyoshi, M.; Aoyama, M.; Fueda, Y.; Kotani, J. Butyrate and trichostatin A attenuate nuclear factor κ B activation and tumor necrosis factor α secretion and increase prostaglandin E2 secretion in human peripheral blood mononuclear cells. *Nutr. Res.* **2008**, *28*, 321–328. [[CrossRef](#)] [[PubMed](#)]
217. Cox, M.A.; Jackson, J.; Stanton, M.; Rojas-Triana, A.; Bober, L.; Laverty, M.; Yang, X.; Zhu, F.; Liu, J.; Wang, S.; et al. Short-chain fatty acids act as antiinflammatory mediators by regulating prostaglandin E2 and cytokines. *World J. Gastroenterol.* **2009**, *15*, 5549–5557. [[CrossRef](#)] [[PubMed](#)]
218. McLoughlin, R.F.; Berthon, B.S.; Jensen, M.E.; Baines, K.J.; Wood, L.G. Short-chain fatty acids, prebiotics, synbiotics, and systemic inflammation: a systematic review and meta-analysis. *Am. J. Clin. Nutr.* **2017**, *106*, 930–945. [[CrossRef](#)] [[PubMed](#)]
219. Tedelind, S.; Westberg, F.; Kjerrulf, M.; Vidal, A. Antiinflammatory properties of the short-chain fatty acids acetate and propionate: A study with relevance to inflammatory bowel disease. *World J. Gastroenterol.* **2007**, *13*, 2826–2832. [[CrossRef](#)] [[PubMed](#)]
220. Park, G.Y.; Joo, M.; Pedchenko, T.; Blackwell, T.S.; Christman, J.W. Regulation of macrophage cyclooxygenase-2 gene expression by modifications of histone H3. *Am. J. Physiol. Lung Cell. Mol. Physiol.* **2004**, *286*, L956–L962. [[CrossRef](#)] [[PubMed](#)]
221. Menzel, T.; Lührs, H.; Zirlik, S.; Schaubert, J.; Kudlich, T.; Gerke, T.; Gostner, A.; Neumann, M.; Melcher, R.; Scheppach, W. Butyrate inhibits leukocyte adhesion to endothelial cells via modulation of VCAM-1. *Inflamm. Bowel Dis.* **2004**, *10*, 122–128. [[CrossRef](#)] [[PubMed](#)]
222. Zapolska-Downar, D.; Naruszewicz, M. Propionate reduces the cytokine-induced VCAM-1 and ICAM-1 expression by inhibiting nuclear factor- κ B (NF- κ B) activation. *J. Physiol. Pharmacol.* **2009**, *60*, 123–131. [[PubMed](#)]
223. Böhmig, G.A.; Krieger, P.M.; Säemann, M.D.; Wenhardt, C.; Pohanka, E.; Zlabinger, G.J. n-Butyrate downregulates the stimulatory function of peripheral blood-derived antigen-presenting cells: A potential mechanism for modulating T-cell responses by short-chain fatty acids. *Immunology* **1997**, *92*, 234–243. [[CrossRef](#)]
224. Blandino, G.; Inturri, R.; Lazzara, F.; Di Rosa, M.; Malaguarnera, L. Impact of gut microbiota on diabetes mellitus. *Diabetes MeTab.* **2016**, *42*, 303–315. [[CrossRef](#)] [[PubMed](#)]

225. Lin, M.Y.; Yen, C.L. Antioxidative ability of lactic acid bacteria. *J. Agric. Food Chem.* **1999**, *47*, 1460–1466. [[CrossRef](#)]
226. Wang, Y.; Wu, Y.; Wang, Y.; Xu, H.; Mei, X.; Yu, D.; Wang, Y.; Li, W. Antioxidant Properties of Probiotic Bacteria. *Nutrients* **2017**, *9*, 521. [[CrossRef](#)] [[PubMed](#)]
227. Salehi-Abargouei, A.; Ghasvand, R.; Hariri, M. Prebiotics, Prosynbiotics and Synbiotics: Can They Reduce Plasma Oxidative Stress Parameters? A Systematic Review. *Probiotics Antimicrob. Proteins* **2017**, *9*, 1–11. [[CrossRef](#)] [[PubMed](#)]
228. Hemaiswarya, S.; Raja, R.; Ravikumar, R.; Carvalho, I.S. Mechanism of Action of Probiotics. *Braz. Arch. Biol. Technol.* **2013**, *56*, 113–119. [[CrossRef](#)]
229. Dai, Z.L.; Wu, G.; Zhu, W.Y. Amino acid metabolism in intestinal bacteria: Links between gut ecology and host health. *Front. Biosci.* **2011**, *16*, 1768–1786. [[CrossRef](#)]
230. Mortensen, P.B.; Holtug, K.; Bonnén, H.; Clausen, M.R. The degradation of amino acids, proteins, and blood to short-chain fatty acids in colon is prevented by lactulose. *Gastroenterology* **1990**, *98*, 353–360. [[CrossRef](#)]
231. Nordgaard, I.; Mortensen, P.B.; Langkilde, A.M. Small intestinal malabsorption and colonic fermentation of resistant starch and resistant peptides to short-chain fatty acids. *Nutrition* **1995**, *11*, 129–137. [[PubMed](#)]
232. Barker, H.A. Amino acid degradation by anaerobic bacteria. *Annu. Rev. Biochem.* **1981**, *50*, 23–40. [[CrossRef](#)]
233. Newsholme, P.; Brennan, L.; Bender, K. Amino Acid Metabolism, β -Cell Function, and Diabetes. *Diabetes* **2006**, *55*, S39–S47. [[CrossRef](#)]
234. McCormack, S.E.; Shaham, O.; McCarthy, M.A.; Deik, A.A.; Wang, T.J.; Gerszten, R.E.; Clish, C.B.; Mootha, V.K.; Grinspoon, S.K.; Fleischman, A. Circulating branched-chain amino acid concentrations are associated with obesity and future insulin resistance in children and adolescents. *Pediatr. Obes.* **2013**, *8*, 52–61. [[CrossRef](#)]
235. Wang, T.J.; Larson, M.G.; Vasan, R.S.; Cheng, S.; Rhee, E.P.; McCabe, E.; Lewis, G.D.; Fox, C.S.; Jacques, P.F.; Fernandez, C.; et al. Metabolite profiles and the risk of developing diabetes. *Nat. Med.* **2011**, *17*, 448–453. [[CrossRef](#)]
236. Conway, P.L. Probiotics and human health: The state-of-the-art and future perspectives. *Scand. J. Nutr.* **2001**, *45*, 13–21. [[CrossRef](#)]
237. Connolly, E.; Abrahamsson, T.; Björkstén, B. Safety of D(-)-lactic acid producing bacteria in the human infant. *J. Pediatr. Gastroenterol. Nutr.* **2005**, *41*, 489–492. [[CrossRef](#)] [[PubMed](#)]
238. Borriello, S.P.; Hammes, W.P.; Holzapfel, W.; Marteau, P.; Schrezenmeir, J.; Vaara, M.; Valtonen, V. Safety of probiotics that contain lactobacilli or bifidobacteria. *Clin. Infect. Dis.* **2003**, *36*, 775–780. [[CrossRef](#)] [[PubMed](#)]
239. Doron, S.; Snyderman, D.R. Risk and safety of probiotics. *Clin. Infect. Dis.* **2015**, *60*, S129–S134. [[CrossRef](#)]
240. Sorokulova, I. Preclinical testing in the development of probiotics: A regulatory perspective with *Bacillus* strains as an example. *Clin. Infect. Dis.* **2008**, *46*, S92–S95. [[CrossRef](#)] [[PubMed](#)]
241. Verna, E.C.; Lucak, S. Use of probiotics in gastrointestinal disorders: What to recommend? *Therap. Adv. Gastroenterol.* **2010**, *3*, 307–319. [[CrossRef](#)]
242. Schjørring, S.; Kroghelt, K.A. Assessment of bacterial antibiotic resistance transfer in the gut. *Int. J. Microbiol.* **2011**, *2011*, 1–10. [[CrossRef](#)] [[PubMed](#)]
243. Borchers, A.T.; Selmi, C.; Meyers, F.J.; Keen, C.L.; Gershwin, M.E. Probiotics and immunity. *J. Gastroenterol.* **2009**, *44*, 26–46. [[CrossRef](#)]
244. de Simone, C. The Unregulated Probiotic Market. *Clin. Gastroenterol. Hepatol.* **2018**. [[CrossRef](#)]
245. Vieira, A.T.; Teixeira, M.M.; Martins, F.S. The role of probiotics and prebiotics in inducing gut immunity. *Front. Immunol.* **2013**, *4*, 445. [[CrossRef](#)] [[PubMed](#)]
246. Foligné, B.; Daniel, C.; Pot, B. Probiotics from research to market: The possibilities, risks and challenges. *Curr. Opin. Microbiol.* **2013**, *16*, 284–292. [[CrossRef](#)] [[PubMed](#)]

